PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
29190898-9	2017	TMZ treatment alleviated PAB-induced acute RHF by activating PRAS40 and upregulatingPGC-1alpha, PGC-1beta, PPARalpha, PPARdelta, and PDK4.	Temozolomide	0-3	peroxisome proliferator-activated receptor delta	Rattus norvegicus	118-127
29190898-5	2017	TMZ also reversed downregulation of peroxisome proliferator-activated receptor gamma coactivator 1-beta (PGC-1beta) and peroxisome proliferator-activated receptor alpha (PPARalpha) by PAB and up-regulates peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), peroxisome proliferator-activated receptor delta (PPARdelta) and pyruvate dehydrogenase kinase isoform 4 (PDK4).	Temozolomide	0-3	peroxisome proliferator-activated receptor delta	Rattus norvegicus	288-336
28034288-2	2018	Studies have shown that GW0742 has off target, non- PPARbeta/delta effects in the cell although there are some key questions that remain to be addressed in respect to the significance of this control on vascular tone.	GW0742	24-30	peroxisome proliferator-activated receptor delta	Rattus norvegicus	52-60
28034288-4	2018	RESULTS: Our data shows that the PPARbeta/delta agonist GW0742 (10-7M) inhibits contractile responses to U46619 and phenylephrine, and that these responses are similar in normal and Streptozotocin (STZ) diabetic rat aorta.	GW0742	56-62	peroxisome proliferator-activated receptor delta	Rattus norvegicus	33-41
28034288-4	2018	RESULTS: Our data shows that the PPARbeta/delta agonist GW0742 (10-7M) inhibits contractile responses to U46619 and phenylephrine, and that these responses are similar in normal and Streptozotocin (STZ) diabetic rat aorta.	15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid	105-111	peroxisome proliferator-activated receptor delta	Rattus norvegicus	33-41
28034288-4	2018	RESULTS: Our data shows that the PPARbeta/delta agonist GW0742 (10-7M) inhibits contractile responses to U46619 and phenylephrine, and that these responses are similar in normal and Streptozotocin (STZ) diabetic rat aorta.	Phenylephrine	116-129	peroxisome proliferator-activated receptor delta	Rattus norvegicus	33-41
28034288-4	2018	RESULTS: Our data shows that the PPARbeta/delta agonist GW0742 (10-7M) inhibits contractile responses to U46619 and phenylephrine, and that these responses are similar in normal and Streptozotocin (STZ) diabetic rat aorta.	Streptozocin	198-201	peroxisome proliferator-activated receptor delta	Rattus norvegicus	33-41
28962559-9	2017	RESULTS: Cisplatin significantly decreased the expression levels of PON-1, PON-3, PPAR-delta and GPX whereas significantly increased PON-2 expression levels.	Cisplatin	9-18	peroxisome proliferator-activated receptor delta	Rattus norvegicus	82-92
29190898-5	2017	TMZ also reversed downregulation of peroxisome proliferator-activated receptor gamma coactivator 1-beta (PGC-1beta) and peroxisome proliferator-activated receptor alpha (PPARalpha) by PAB and up-regulates peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), peroxisome proliferator-activated receptor delta (PPARdelta) and pyruvate dehydrogenase kinase isoform 4 (PDK4).	Temozolomide	0-3	peroxisome proliferator-activated receptor delta	Rattus norvegicus	338-347
29190898-9	2017	TMZ treatment alleviated PAB-induced acute RHF by activating PRAS40 and upregulatingPGC-1alpha, PGC-1beta, PPARalpha, PPARdelta, and PDK4.	4-Aminobenzoic Acid	25-28	peroxisome proliferator-activated receptor delta	Rattus norvegicus	118-127
28440451-1	2017	The aim of the present study was to investigate the protective effect of the selective peroxisome proliferator-activated receptor delta (PPARdelta) agonist GW501516 (GW) on lipopolysaccharide (LPS)-induced apoptosis in the rat cardiomyoblast cell line H9c2, and to investigate the possible underlying mechanisms.	GW 501516	156-164	peroxisome proliferator-activated receptor delta	Rattus norvegicus	87-135
28621328-6	2017	In vitro, carbacyclin induced proliferation of neonatal and adult mononuclear rat cardiomyocytes via a peroxisome proliferator-activated receptor delta (PPARdelta)/PDK1/p308Akt/GSK3beta/beta-catenin pathway.	carboprostacyclin	10-21	peroxisome proliferator-activated receptor delta	Rattus norvegicus	103-151
28621328-6	2017	In vitro, carbacyclin induced proliferation of neonatal and adult mononuclear rat cardiomyocytes via a peroxisome proliferator-activated receptor delta (PPARdelta)/PDK1/p308Akt/GSK3beta/beta-catenin pathway.	carboprostacyclin	10-21	peroxisome proliferator-activated receptor delta	Rattus norvegicus	153-162
28672855-0	2017	Ginsenoside Rh2 Improves Cardiac Fibrosis via PPARdelta-STAT3 Signaling in Type 1-Like Diabetic Rats.	ginsenoside Rh2	0-15	peroxisome proliferator-activated receptor delta	Rattus norvegicus	46-55
28672855-6	2017	The effects of Rh2 were reversed by GSK0660 at a dose sufficient to inhibit peroxisome proliferator-activated receptor delta (PPARdelta) in STZ-diabetic rats.	rh2	15-18	peroxisome proliferator-activated receptor delta	Rattus norvegicus	76-124
28672855-6	2017	The effects of Rh2 were reversed by GSK0660 at a dose sufficient to inhibit peroxisome proliferator-activated receptor delta (PPARdelta) in STZ-diabetic rats.	rh2	15-18	peroxisome proliferator-activated receptor delta	Rattus norvegicus	126-135
28672855-6	2017	The effects of Rh2 were reversed by GSK0660 at a dose sufficient to inhibit peroxisome proliferator-activated receptor delta (PPARdelta) in STZ-diabetic rats.	GSK0660	36-43	peroxisome proliferator-activated receptor delta	Rattus norvegicus	76-124
28672855-6	2017	The effects of Rh2 were reversed by GSK0660 at a dose sufficient to inhibit peroxisome proliferator-activated receptor delta (PPARdelta) in STZ-diabetic rats.	GSK0660	36-43	peroxisome proliferator-activated receptor delta	Rattus norvegicus	126-135
28672855-6	2017	The effects of Rh2 were reversed by GSK0660 at a dose sufficient to inhibit peroxisome proliferator-activated receptor delta (PPARdelta) in STZ-diabetic rats.	Streptozocin	140-143	peroxisome proliferator-activated receptor delta	Rattus norvegicus	76-124
28672855-6	2017	The effects of Rh2 were reversed by GSK0660 at a dose sufficient to inhibit peroxisome proliferator-activated receptor delta (PPARdelta) in STZ-diabetic rats.	Streptozocin	140-143	peroxisome proliferator-activated receptor delta	Rattus norvegicus	126-135
28672855-8	2017	Rh2 restored the decreased PPARdelta expression level in high glucose-cultured cardiomyocytes.	rh2	0-3	peroxisome proliferator-activated receptor delta	Rattus norvegicus	27-36
28672855-8	2017	Rh2 restored the decreased PPARdelta expression level in high glucose-cultured cardiomyocytes.	Glucose	62-69	peroxisome proliferator-activated receptor delta	Rattus norvegicus	27-36
28672855-10	2017	These effects of Rh2 were reversed by GSK0660 or siRNA specific for PPARdelta Taken together, PPARdelta activation may inhibit STAT3 activation to reduce CCN2 and fibronectin expression in diabetic rats with cardiac fibrosis.	rh2	17-20	peroxisome proliferator-activated receptor delta	Rattus norvegicus	68-77
28672855-10	2017	These effects of Rh2 were reversed by GSK0660 or siRNA specific for PPARdelta Taken together, PPARdelta activation may inhibit STAT3 activation to reduce CCN2 and fibronectin expression in diabetic rats with cardiac fibrosis.	rh2	17-20	peroxisome proliferator-activated receptor delta	Rattus norvegicus	94-103
28672855-11	2017	Moreover, Rh2 improves cardiac function and fibrosis by increasing PPARdelta signaling.	rh2	10-13	peroxisome proliferator-activated receptor delta	Rattus norvegicus	67-76
28440451-1	2017	The aim of the present study was to investigate the protective effect of the selective peroxisome proliferator-activated receptor delta (PPARdelta) agonist GW501516 (GW) on lipopolysaccharide (LPS)-induced apoptosis in the rat cardiomyoblast cell line H9c2, and to investigate the possible underlying mechanisms.	GW 501516	156-164	peroxisome proliferator-activated receptor delta	Rattus norvegicus	137-146
28440451-1	2017	The aim of the present study was to investigate the protective effect of the selective peroxisome proliferator-activated receptor delta (PPARdelta) agonist GW501516 (GW) on lipopolysaccharide (LPS)-induced apoptosis in the rat cardiomyoblast cell line H9c2, and to investigate the possible underlying mechanisms.	GW 501516	156-158	peroxisome proliferator-activated receptor delta	Rattus norvegicus	87-135
28440451-1	2017	The aim of the present study was to investigate the protective effect of the selective peroxisome proliferator-activated receptor delta (PPARdelta) agonist GW501516 (GW) on lipopolysaccharide (LPS)-induced apoptosis in the rat cardiomyoblast cell line H9c2, and to investigate the possible underlying mechanisms.	GW 501516	156-158	peroxisome proliferator-activated receptor delta	Rattus norvegicus	137-146
28440451-9	2017	ZnPP-IX, an inhibitor of HO-1, reversed the inhibitory effect of GW on LPS-induced NF-kappaB activation, leading to the attenuation of PPARdelta-mediated apoptosis resistance.	zinc protoporphyrin	0-7	peroxisome proliferator-activated receptor delta	Rattus norvegicus	135-144
28440451-9	2017	ZnPP-IX, an inhibitor of HO-1, reversed the inhibitory effect of GW on LPS-induced NF-kappaB activation, leading to the attenuation of PPARdelta-mediated apoptosis resistance.	GW 501516	65-67	peroxisome proliferator-activated receptor delta	Rattus norvegicus	135-144
27881385-3	2017	Preclinical studies suggest that pharmacological PPARbeta/delta activation induces antihypertensive effects in direct [spontaneously hypertensive rat (SHR), ANG II, and DOCA-salt] and indirect (dyslipemic and gestational) models of hypertension, associated with end-organ damage protection.	Desoxycorticosterone Acetate	169-173	peroxisome proliferator-activated receptor delta	Rattus norvegicus	49-57
28327554-4	2017	Activation of PPARbeta/delta by GW0742 and adenoviruses PPARbeta/delta (Ad-PPARbeta/delta) significantly inhibited hemoglobin-induced VSMC phenotypic switch.	GW0742	32-38	peroxisome proliferator-activated receptor delta	Rattus norvegicus	14-22
28327554-5	2017	However, the effects of PPARbeta/delta on VSMC phenotypic switch were partly obstacled in the presence of LY294002, a potent inhibitor of Phosphatidyl-Inositol-3 Kinase-AKT (PI3K/AKT).	vsmc	42-46	peroxisome proliferator-activated receptor delta	Rattus norvegicus	24-32
28327554-5	2017	However, the effects of PPARbeta/delta on VSMC phenotypic switch were partly obstacled in the presence of LY294002, a potent inhibitor of Phosphatidyl-Inositol-3 Kinase-AKT (PI3K/AKT).	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	106-114	peroxisome proliferator-activated receptor delta	Rattus norvegicus	24-32
27881385-3	2017	Preclinical studies suggest that pharmacological PPARbeta/delta activation induces antihypertensive effects in direct [spontaneously hypertensive rat (SHR), ANG II, and DOCA-salt] and indirect (dyslipemic and gestational) models of hypertension, associated with end-organ damage protection.	Salts	174-178	peroxisome proliferator-activated receptor delta	Rattus norvegicus	49-57
27592051-0	2016	Ramipril restores PPARbeta/delta and PPARgamma expressions and reduces cardiac NADPH oxidase but fails to restore cardiac function and accompanied myosin heavy chain ratio shift in severe anthracycline-induced cardiomyopathy in rat.	Ramipril	0-8	peroxisome proliferator-activated receptor delta	Rattus norvegicus	18-26
27789312-0	2017	PPARbeta/delta activation protects against corticosterone-induced ER stress in astrocytes by inhibiting the CpG hypermethylation of microRNA-181a.	Corticosterone	43-57	peroxisome proliferator-activated receptor delta	Rattus norvegicus	0-8
27789312-5	2017	Our research found that corticosterone treatment resulted in astrocyte damage and reduced the expression of PPARbeta/delta.	Corticosterone	24-38	peroxisome proliferator-activated receptor delta	Rattus norvegicus	108-116
27789312-6	2017	GW0742, a selective and high-affinity PPARbeta/delta agonist, attenuated the corticosterone-induced astrocyte damage, but also significantly reversed the increase in the expression of GRP78 and CHOP, the two predominant proteins in endoplasmic reticulum (ER) stress.	GW0742	0-6	peroxisome proliferator-activated receptor delta	Rattus norvegicus	38-46
27789312-9	2017	Finally, we demonstrated that PPARbeta/delta activation by GW0742 noticeably inhibited the activities and expression of DNA methyltransferases, and reduced the corticosterone-induced CpG island hypermethylation of microRNA-181a1 in astrocytes.	GW0742	59-65	peroxisome proliferator-activated receptor delta	Rattus norvegicus	30-38
27789312-9	2017	Finally, we demonstrated that PPARbeta/delta activation by GW0742 noticeably inhibited the activities and expression of DNA methyltransferases, and reduced the corticosterone-induced CpG island hypermethylation of microRNA-181a1 in astrocytes.	Corticosterone	160-174	peroxisome proliferator-activated receptor delta	Rattus norvegicus	30-38
28680330-3	2017	Gene expression of the foxp3, raralpha, rarbeta, rxrbeta, and ppar beta/delta and protein expression of the Raralpha, Rarbeta, and Rxrbeta in cells after stimulation with ATRA were also investigated.	Tretinoin	171-175	peroxisome proliferator-activated receptor delta	Rattus norvegicus	62-71
27592051-9	2016	Simultaneously, while high-dose daunorubicin significantly decreased PPARbeta/delta and PPARgama mRNA, ramipril normalized these abnormalities.	Daunorubicin	32-44	peroxisome proliferator-activated receptor delta	Rattus norvegicus	69-77
27631677-2	2016	Peroxisome proliferator-activated receptor delta (PPARdelta), a vital regulator of glucose and lipid metabolism, may reduce fatty acid-induced pancreatic beta cell lipotoxicity in diabetes.	Glucose	83-90	peroxisome proliferator-activated receptor delta	Rattus norvegicus	0-48
27631677-2	2016	Peroxisome proliferator-activated receptor delta (PPARdelta), a vital regulator of glucose and lipid metabolism, may reduce fatty acid-induced pancreatic beta cell lipotoxicity in diabetes.	Glucose	83-90	peroxisome proliferator-activated receptor delta	Rattus norvegicus	50-59
27631677-2	2016	Peroxisome proliferator-activated receptor delta (PPARdelta), a vital regulator of glucose and lipid metabolism, may reduce fatty acid-induced pancreatic beta cell lipotoxicity in diabetes.	Fatty Acids	124-134	peroxisome proliferator-activated receptor delta	Rattus norvegicus	0-48
27631677-2	2016	Peroxisome proliferator-activated receptor delta (PPARdelta), a vital regulator of glucose and lipid metabolism, may reduce fatty acid-induced pancreatic beta cell lipotoxicity in diabetes.	Fatty Acids	124-134	peroxisome proliferator-activated receptor delta	Rattus norvegicus	50-59
27631677-4	2016	In this study, we investigated the effect of activation of PPARdelta on palmitate-induced beta cell apoptosis, and we explored the potential mechanism of the antiapoptotic effect.	Palmitates	72-81	peroxisome proliferator-activated receptor delta	Rattus norvegicus	59-68
27413020-0	2016	Activation of PPARbeta/delta prevents hyperglycaemia-induced impairment of Kv7 channels and cAMP-mediated relaxation in rat coronary arteries.	Cyclic AMP	92-96	peroxisome proliferator-activated receptor delta	Rattus norvegicus	14-22
27413020-3	2016	Herein, we aimed to analyse the possible protective effects of the PPARbeta/delta agonist GW0742 on the hyperglycaemic-induced impairment of cAMP-induced relaxation and Kv channel function in rat CA.	GW0742	90-96	peroxisome proliferator-activated receptor delta	Rattus norvegicus	67-75
27413020-3	2016	Herein, we aimed to analyse the possible protective effects of the PPARbeta/delta agonist GW0742 on the hyperglycaemic-induced impairment of cAMP-induced relaxation and Kv channel function in rat CA.	Cyclic AMP	141-145	peroxisome proliferator-activated receptor delta	Rattus norvegicus	67-75
27413020-5	2016	The protective effect of GW0742 was supressed by a PPARbeta/delta antagonist.	GW0742	25-31	peroxisome proliferator-activated receptor delta	Rattus norvegicus	51-59
27413020-13	2016	Our results reveal that the PPARbeta/delta agonist GW0742 prevents the impairment of the cAMP-mediated relaxation in CA under HG.	GW0742	51-57	peroxisome proliferator-activated receptor delta	Rattus norvegicus	28-36
27413020-13	2016	Our results reveal that the PPARbeta/delta agonist GW0742 prevents the impairment of the cAMP-mediated relaxation in CA under HG.	Cyclic AMP	89-93	peroxisome proliferator-activated receptor delta	Rattus norvegicus	28-36
26960306-0	2015	Effect of Atorvastatin on Expression of Peroxisome Proliferator-activated Receptor Beta/delta in Angiotensin II-induced Hypertrophic Myocardial Cells In Vitro.	Atorvastatin	10-22	peroxisome proliferator-activated receptor delta	Rattus norvegicus	40-93
27519769-0	2016	Telmisartan improves cardiac fibrosis in diabetes through peroxisome proliferator activated receptor delta (PPARdelta): from bedside to bench.	Telmisartan	0-11	peroxisome proliferator-activated receptor delta	Rattus norvegicus	58-106
27519769-0	2016	Telmisartan improves cardiac fibrosis in diabetes through peroxisome proliferator activated receptor delta (PPARdelta): from bedside to bench.	Telmisartan	0-11	peroxisome proliferator-activated receptor delta	Rattus norvegicus	108-117
27519769-9	2016	After incubation with 30 mM glucose, rat cardiomyocytes showed a significant down-regulation of PPARdelta.	Glucose	28-35	peroxisome proliferator-activated receptor delta	Rattus norvegicus	96-105
26936652-7	2016	Thus, PPARdelta/PGC-1alpha-dependent signals together reduced insulin-dependent glucose uptake and adenosine triphosphate (ATP) production.	Glucose	80-87	peroxisome proliferator-activated receptor delta	Rattus norvegicus	6-15
26936652-7	2016	Thus, PPARdelta/PGC-1alpha-dependent signals together reduced insulin-dependent glucose uptake and adenosine triphosphate (ATP) production.	Adenosine Triphosphate	99-121	peroxisome proliferator-activated receptor delta	Rattus norvegicus	6-15
26936652-7	2016	Thus, PPARdelta/PGC-1alpha-dependent signals together reduced insulin-dependent glucose uptake and adenosine triphosphate (ATP) production.	Adenosine Triphosphate	123-126	peroxisome proliferator-activated receptor delta	Rattus norvegicus	6-15
26862756-3	2016	Animals were assigned to the following groups: sham-operated control group, left anterior descending coronary artery ligation (MI) group, or MI with administration of the PPAR-delta agonist GW610742 group.	GW 610742	190-198	peroxisome proliferator-activated receptor delta	Rattus norvegicus	171-181
26628385-9	2016	In addition, GW0742, a specific agonist of PPARbeta/delta, was used to treat SAH in rats, the effects of which were evaluated by neurological scoring and Evans blue extravasation.	GW0742	13-19	peroxisome proliferator-activated receptor delta	Rattus norvegicus	43-51
27519769-10	2016	Interestingly, the increased expression of fibrosis-associated proteins, including signal transducer and activator of transcription 3 (STAT3) was attenuated by the co-incubation of GW0742, a PPARdelta agonist.	GW0742	181-187	peroxisome proliferator-activated receptor delta	Rattus norvegicus	191-200
27519769-13	2016	Conversely, in the presence of GSK0660, a PPARdelta inhibitor, the protective effects of telmisartan were diminished.	GSK0660	31-38	peroxisome proliferator-activated receptor delta	Rattus norvegicus	42-51
27519769-13	2016	Conversely, in the presence of GSK0660, a PPARdelta inhibitor, the protective effects of telmisartan were diminished.	Telmisartan	89-100	peroxisome proliferator-activated receptor delta	Rattus norvegicus	42-51
27519769-14	2016	CONCLUSION: Telmisartan improved the hyperglycemia-induced cardiac fibrosis through the PPARdelta/STAT3 pathway.	Telmisartan	12-23	peroxisome proliferator-activated receptor delta	Rattus norvegicus	88-97
27519769-15	2016	Graphical abstract Summary of the mechanism of telmisartan"s effect on the suppression of hyperglycemia-induced cardiac fibrosis through PPARdelta instead of the AMPK pathway.	Telmisartan	47-58	peroxisome proliferator-activated receptor delta	Rattus norvegicus	137-146
26686607-1	2016	Prostacyclin (PGI2) is a key mediator involved in cardiovascular homeostasis, acting predominantly on two receptor types; cell surface IP receptor and cytosolic peroxisome proliferator activated receptor (PPAR) beta/delta.	Epoprostenol	0-12	peroxisome proliferator-activated receptor delta	Rattus norvegicus	205-209
26686607-1	2016	Prostacyclin (PGI2) is a key mediator involved in cardiovascular homeostasis, acting predominantly on two receptor types; cell surface IP receptor and cytosolic peroxisome proliferator activated receptor (PPAR) beta/delta.	Epoprostenol	14-18	peroxisome proliferator-activated receptor delta	Rattus norvegicus	205-209
26686607-3	2016	Here we used computational chemistry methods to investigate the potential for PGI2, beraprost (IP receptor agonist), and GW0742 (PPARbeta/delta agonist), to bind to nuclear receptors, confirmed with pharmacological methods.	GW0742	121-127	peroxisome proliferator-activated receptor delta	Rattus norvegicus	129-137
24806616-9	2014	In contrast to cyclooxygenase 2, the cycloheximide-sensitive PPARbeta/delta expression was not responsive to nuclear factor kappa-light-chain-enhancer of activated B cells inhibition.	Cycloheximide	37-50	peroxisome proliferator-activated receptor delta	Rattus norvegicus	61-69
26558146-4	2015	PPARbeta/delta is more broadly expressed and is implicated in fatty acid oxidation, keratinocyte differentiation, wound healing, and macrophage response to very low density lipoprotein metabolism.	Fatty Acids	62-72	peroxisome proliferator-activated receptor delta	Rattus norvegicus	0-8
26055348-11	2015	Furthermore, resveratrol increased the expression of peroxisome proliferator-activated receptor delta, while decreasing the expression of ATP citrate lyase, suppressor of cytokine signaling-3, and interleukin-1beta.	Resveratrol	13-24	peroxisome proliferator-activated receptor delta	Rattus norvegicus	53-101
26055348-12	2015	Our data suggest that resveratrol can prevent hepatic ER stress and regulate the expression of peroxisome proliferator-activated receptor delta, ATP citrate lyase, suppressor of cytokine signaling-3, tumor necrosis factor alpha, and interleukin-1beta in diet-induced obese rats, and these effects likely contribute to resveratrol"s protective function against excessive accumulation of fat in the liver.	Resveratrol	22-33	peroxisome proliferator-activated receptor delta	Rattus norvegicus	95-143
25810039-4	2015	The latter activated the nuclear peroxisome proliferator-activated receptor-delta (PPARdelta), which in turn augmented glucose-stimulated insulin secretion.	Glucose	119-126	peroxisome proliferator-activated receptor delta	Rattus norvegicus	33-81
25810039-4	2015	The latter activated the nuclear peroxisome proliferator-activated receptor-delta (PPARdelta), which in turn augmented glucose-stimulated insulin secretion.	Glucose	119-126	peroxisome proliferator-activated receptor delta	Rattus norvegicus	83-92
25810039-10	2015	Importantly, released arachidonic acid and linoleic acid were subjected to peroxidation, resulting in the generation of 4-HNE, which further augmented insulin secretion by activating PPARdelta in beta cells.	Arachidonic Acid	22-38	peroxisome proliferator-activated receptor delta	Rattus norvegicus	183-192
25810039-10	2015	Importantly, released arachidonic acid and linoleic acid were subjected to peroxidation, resulting in the generation of 4-HNE, which further augmented insulin secretion by activating PPARdelta in beta cells.	Linoleic Acid	43-56	peroxisome proliferator-activated receptor delta	Rattus norvegicus	183-192
25810039-10	2015	Importantly, released arachidonic acid and linoleic acid were subjected to peroxidation, resulting in the generation of 4-HNE, which further augmented insulin secretion by activating PPARdelta in beta cells.	4-hydroxy-2-nonenal	120-125	peroxisome proliferator-activated receptor delta	Rattus norvegicus	183-192
25941823-0	2015	Polydatin Restores Endothelium-Dependent Relaxation in Rat Aorta Rings Impaired by High Glucose: A Novel Insight into the PPARbeta-NO Signaling Pathway.	polydatin	0-9	peroxisome proliferator-activated receptor delta	Rattus norvegicus	122-130
25941823-7	2015	Polydatin"s effects were mediated via promoting the expression of endothelial NO synthase (eNOS), enhancing eNOS activity and decreasing the inducible NOS (iNOS) level, finally resulting in a beneficial increase in NO release, which probably, at least in part, through activation of the PPARbeta signaling pathway.	polydatin	0-9	peroxisome proliferator-activated receptor delta	Rattus norvegicus	287-295
25941823-8	2015	The results provided a novel insight into polydatin action, via PPARbeta-NO signaling pathways, in restoring endothelial function in high glucose conditions.	polydatin	42-51	peroxisome proliferator-activated receptor delta	Rattus norvegicus	64-72
25828396-0	2015	Activation of PPARbeta/delta protects cardiac myocytes from oxidative stress-induced apoptosis by suppressing generation of reactive oxygen/nitrogen species and expression of matrix metalloproteinases.	reactive oxygen/nitrogen species	124-156	peroxisome proliferator-activated receptor delta	Rattus norvegicus	14-22
25828396-5	2015	In this study we sought to investigate the potential beneficial effects evoked by activation of PPARbeta/delta under the setting of oxidative stress induced by H2O2 in adult rat cardiac myocytes.	Hydrogen Peroxide	160-164	peroxisome proliferator-activated receptor delta	Rattus norvegicus	96-104
25828396-6	2015	The selective PPARbeta/delta agonist GW0742 inhibited the H2O2-induced apoptosis and increased cell viability.	GW0742	37-43	peroxisome proliferator-activated receptor delta	Rattus norvegicus	14-22
25828396-6	2015	The selective PPARbeta/delta agonist GW0742 inhibited the H2O2-induced apoptosis and increased cell viability.	Hydrogen Peroxide	58-62	peroxisome proliferator-activated receptor delta	Rattus norvegicus	14-22
25147052-9	2015	Finally, agonists for PPARbeta (GW0742) or PPARgamma (GW1929) increased E-FABP expression and enhanced the resistance of NGFDPC12 cells to PAM-LTx.	GW0742	32-38	peroxisome proliferator-activated receptor delta	Rattus norvegicus	22-30
24527778-0	2014	PPARbeta activation restores the high glucose-induced impairment of insulin signalling in endothelial cells.	Glucose	38-45	peroxisome proliferator-activated receptor delta	Rattus norvegicus	0-8
24774438-9	2014	CONCLUSIONS: The study suggests the neuroprotective effect of the PPAR-beta/delta ligand GW0742 in acute ischemic stroke by a mechanism that may involve its anti-inflammatory and antiapoptotic action.	GW0742	89-95	peroxisome proliferator-activated receptor delta	Rattus norvegicus	66-75
24780550-1	2014	Peroxisome proliferator-activated receptor (PPAR)-beta/delta is a transcription factor that belongs to the PPAR family, but the role of PPAR-beta/delta in acute lung injury (ALI) induced by hyperbaric oxygen is unknown.	Oxygen	201-207	peroxisome proliferator-activated receptor delta	Rattus norvegicus	44-48
24780550-1	2014	Peroxisome proliferator-activated receptor (PPAR)-beta/delta is a transcription factor that belongs to the PPAR family, but the role of PPAR-beta/delta in acute lung injury (ALI) induced by hyperbaric oxygen is unknown.	Oxygen	201-207	peroxisome proliferator-activated receptor delta	Rattus norvegicus	136-145
24780550-6	2014	However, administration of the PPAR-beta/delta antagonist GSK0660 abolished these protective effects.	GSK0660	58-65	peroxisome proliferator-activated receptor delta	Rattus norvegicus	31-40
24527778-2	2014	We analysed the effects of the PPARbeta/delta (PPARbeta) agonists, GW0742 and L165041, on impaired insulin signalling induced by high glucose in HUVECs and aortic and mesenteric arteries from diabetic rats.	Glucose	134-141	peroxisome proliferator-activated receptor delta	Rattus norvegicus	31-39
24527778-2	2014	We analysed the effects of the PPARbeta/delta (PPARbeta) agonists, GW0742 and L165041, on impaired insulin signalling induced by high glucose in HUVECs and aortic and mesenteric arteries from diabetic rats.	Glucose	134-141	peroxisome proliferator-activated receptor delta	Rattus norvegicus	47-55
24527778-7	2014	The co-incubation with the PPARbeta agonists GW0742 or L165041 prevented all these effects induced by high glucose.	GW0742	45-51	peroxisome proliferator-activated receptor delta	Rattus norvegicus	27-35
24527778-7	2014	The co-incubation with the PPARbeta agonists GW0742 or L165041 prevented all these effects induced by high glucose.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	55-62	peroxisome proliferator-activated receptor delta	Rattus norvegicus	27-35
24527778-7	2014	The co-incubation with the PPARbeta agonists GW0742 or L165041 prevented all these effects induced by high glucose.	Glucose	107-114	peroxisome proliferator-activated receptor delta	Rattus norvegicus	27-35
24527778-8	2014	In turn, the effects induced by the agonists were suppressed when HUVEC were also incubated with the PPARbeta antagonist GSK0660, the pyruvate dehydrogenase kinase (PDK)4 inhibitor dichloroacetate or after knockdown of both PPARbeta and PDK4 with siRNA.	GSK0660	121-128	peroxisome proliferator-activated receptor delta	Rattus norvegicus	101-109
24527778-8	2014	In turn, the effects induced by the agonists were suppressed when HUVEC were also incubated with the PPARbeta antagonist GSK0660, the pyruvate dehydrogenase kinase (PDK)4 inhibitor dichloroacetate or after knockdown of both PPARbeta and PDK4 with siRNA.	GSK0660	121-128	peroxisome proliferator-activated receptor delta	Rattus norvegicus	224-232
24527778-8	2014	In turn, the effects induced by the agonists were suppressed when HUVEC were also incubated with the PPARbeta antagonist GSK0660, the pyruvate dehydrogenase kinase (PDK)4 inhibitor dichloroacetate or after knockdown of both PPARbeta and PDK4 with siRNA.	Dichloroacetic Acid	181-196	peroxisome proliferator-activated receptor delta	Rattus norvegicus	101-109
24527778-8	2014	In turn, the effects induced by the agonists were suppressed when HUVEC were also incubated with the PPARbeta antagonist GSK0660, the pyruvate dehydrogenase kinase (PDK)4 inhibitor dichloroacetate or after knockdown of both PPARbeta and PDK4 with siRNA.	Dichloroacetic Acid	181-196	peroxisome proliferator-activated receptor delta	Rattus norvegicus	224-232
24527778-11	2014	CONCLUSION AND IMPLICATIONS: PPARbeta activation in vitro and in vivo restores the endothelial function, preserving the insulin-Akt-eNOS pathway impaired by high glucose, at least in part, through PDK4 activation.	Glucose	162-169	peroxisome proliferator-activated receptor delta	Rattus norvegicus	29-37
24635117-2	2014	In this study, we have investigated the effect of GW0742, a PPAR-beta/delta agonist in rat model of cognitive impairment associated with PD.	GW0742	50-56	peroxisome proliferator-activated receptor delta	Rattus norvegicus	60-69
24337677-0	2014	The PPARbeta/delta agonist GW501516 attenuates peritonitis in peritoneal fibrosis via inhibition of TAK1-NFkappaB pathway in rats.	GW 501516	27-35	peroxisome proliferator-activated receptor delta	Rattus norvegicus	4-12
24635117-4	2014	PPAR-beta/delta agonist GW0742 at a dose of 30 and 100 microg/kg showed significant improvement in cognitive impairments caused by MPTP in rat model of PD as evident from passive avoidance and Morris water maze test.	GW0742	24-30	peroxisome proliferator-activated receptor delta	Rattus norvegicus	0-9
24635117-4	2014	PPAR-beta/delta agonist GW0742 at a dose of 30 and 100 microg/kg showed significant improvement in cognitive impairments caused by MPTP in rat model of PD as evident from passive avoidance and Morris water maze test.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	131-135	peroxisome proliferator-activated receptor delta	Rattus norvegicus	0-9
24513118-0	2014	Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) protects against ceramide-induced cellular toxicity in rat brain astrocytes and neurons by activation of ceramide kinase.	Ceramides	88-96	peroxisome proliferator-activated receptor delta	Rattus norvegicus	0-69
23779049-4	2014	METHOD: We first established a direct stimulatory effect of the PPARdelta agonist (GW 501516) on the HO-1 gene by demonstrating increased luciferase activity in COS-7 cells transfected with a luciferase-HO-1 promoter construct.	GW 501516	83-92	peroxisome proliferator-activated receptor delta	Rattus norvegicus	64-73
24624894-0	2014	Protective role of peroxisome proliferator-activated receptor-beta/delta against pulmonary oxygen toxicity mediated through changes in NOS expression levels.	Oxygen	91-97	peroxisome proliferator-activated receptor delta	Rattus norvegicus	19-72
24624894-1	2014	Recent studies have demonstrated that peroxisome proliferator-activated receptor-beta/delta (PPAR-beta/delta) has a protective effect during lung injury induced by bleomycin and polymicrobial sepsis, but its function in pulmonary oxygen toxicity is unknown.	Bleomycin	164-173	peroxisome proliferator-activated receptor delta	Rattus norvegicus	38-91
24624894-1	2014	Recent studies have demonstrated that peroxisome proliferator-activated receptor-beta/delta (PPAR-beta/delta) has a protective effect during lung injury induced by bleomycin and polymicrobial sepsis, but its function in pulmonary oxygen toxicity is unknown.	Bleomycin	164-173	peroxisome proliferator-activated receptor delta	Rattus norvegicus	93-102
24624894-1	2014	Recent studies have demonstrated that peroxisome proliferator-activated receptor-beta/delta (PPAR-beta/delta) has a protective effect during lung injury induced by bleomycin and polymicrobial sepsis, but its function in pulmonary oxygen toxicity is unknown.	Oxygen	230-236	peroxisome proliferator-activated receptor delta	Rattus norvegicus	93-102
24624894-12	2014	Collectively, these data indicate that PPAR-beta/delta activation can protect against pulmonary oxygen toxicity in the lungs of rats through changes in the expression of NOS.	Oxygen	96-102	peroxisome proliferator-activated receptor delta	Rattus norvegicus	39-48
24513118-4	2014	In the present study, we test the hypothesis that neuroprotection induced by PPARbeta/delta could rely on the regulation of ceramide metabolism.	Ceramides	124-132	peroxisome proliferator-activated receptor delta	Rattus norvegicus	77-85
24513118-5	2014	We found that preincubation of neural cells with the PPARbeta/delta agonist L-165041 exerts significant protection against ceramide-induced cell death.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	76-84	peroxisome proliferator-activated receptor delta	Rattus norvegicus	53-61
24513118-5	2014	We found that preincubation of neural cells with the PPARbeta/delta agonist L-165041 exerts significant protection against ceramide-induced cell death.	Ceramides	123-131	peroxisome proliferator-activated receptor delta	Rattus norvegicus	53-61
24513118-10	2014	Knockdown of PPARbeta/delta and CerK in astrocytes was used to verify that the protective effects of L-165041 are CerK- and PPARbeta/delta-dependent.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	101-109	peroxisome proliferator-activated receptor delta	Rattus norvegicus	13-21
24513118-10	2014	Knockdown of PPARbeta/delta and CerK in astrocytes was used to verify that the protective effects of L-165041 are CerK- and PPARbeta/delta-dependent.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	101-109	peroxisome proliferator-activated receptor delta	Rattus norvegicus	124-132
24513118-12	2014	Thus, we conclude that PPARbeta/delta protects neural cells against ceramide-induced cell death via induction and activation of CerK.	Ceramides	68-76	peroxisome proliferator-activated receptor delta	Rattus norvegicus	23-31
24269940-0	2014	Activation of PPARbeta/delta protects pancreatic beta cells from palmitate-induced apoptosis by upregulating the expression of GLP-1 receptor.	Palmitates	65-74	peroxisome proliferator-activated receptor delta	Rattus norvegicus	14-22
24269940-4	2014	In the present study, we aimed to investigate the underlying molecular mechanisms that PPARbeta/delta activation suppressed apoptosis and improved beta cell function impaired by fatty acids, focusing on contribution of GLP-1R.	Fatty Acids	178-189	peroxisome proliferator-activated receptor delta	Rattus norvegicus	87-95
24128860-1	2014	The purpose of this study was to evaluate the existence of a possible simultaneous regulation of fatty acid (FA) metabolism and lactate production by PPAR alpha and PPAR beta/delta activation in Sertoli cells (SC).	Fatty Acids	97-107	peroxisome proliferator-activated receptor delta	Rattus norvegicus	165-174
24128860-1	2014	The purpose of this study was to evaluate the existence of a possible simultaneous regulation of fatty acid (FA) metabolism and lactate production by PPAR alpha and PPAR beta/delta activation in Sertoli cells (SC).	Lactic Acid	128-135	peroxisome proliferator-activated receptor delta	Rattus norvegicus	165-174
24128860-2	2014	SC cultures obtained from 20-day-old rats were incubated with WY14643 or GW0742-pharmacological activators of PPAR alpha and PPAR beta/delta respectively.	GW0742	73-79	peroxisome proliferator-activated receptor delta	Rattus norvegicus	125-134
24128860-5	2014	Additionally, PPAR beta/delta activation increased lactate production as a consequence of increased pyruvate availability by inhibiting the Pyruvate Dehydrogenase Complex.	Lactic Acid	51-58	peroxisome proliferator-activated receptor delta	Rattus norvegicus	14-23
24128860-5	2014	Additionally, PPAR beta/delta activation increased lactate production as a consequence of increased pyruvate availability by inhibiting the Pyruvate Dehydrogenase Complex.	Pyruvic Acid	100-108	peroxisome proliferator-activated receptor delta	Rattus norvegicus	14-23
23701913-0	2013	Increase of PPARdelta by dopamine mediated via DA-1 receptor-linked phospholipase C pathway in neonatal rat cardiomyocytes.	Dopamine	25-33	peroxisome proliferator-activated receptor delta	Rattus norvegicus	12-21
24128860-7	2014	On the other hand, PPAR beta/delta activation regulates FA metabolism and lactate production ensuring simultaneously the energetic metabolism for SC and germ cells.	Lactic Acid	74-81	peroxisome proliferator-activated receptor delta	Rattus norvegicus	19-28
23225238-0	2013	Increase of peroxisome proliferator-activated receptor delta (PPARdelta) by digoxin to improve lipid metabolism in the heart of diabetic rats.	Digoxin	76-83	peroxisome proliferator-activated receptor delta	Rattus norvegicus	12-60
23701913-3	2013	But the mediation of PPARdelta in cardiac action of dopamine is still unclear.	Dopamine	52-60	peroxisome proliferator-activated receptor delta	Rattus norvegicus	21-30
23701913-6	2013	We silenced PPARdelta by RNAi to identify the major role of PPARdelta in dopamine-induced actions.	Dopamine	73-81	peroxisome proliferator-activated receptor delta	Rattus norvegicus	60-69
23701913-7	2013	RESULTS: Dopamine increases PPARdelta expression and cardiac troponin I (cTnI) phosphorylation in a time- and dose-dependent manner in neonatal rat cardiomyocytes.	Dopamine	9-17	peroxisome proliferator-activated receptor delta	Rattus norvegicus	28-37
23701913-9	2013	The increase of cTnI phosphorylation by dopamine was also inhibited in cardiomyocytes silenced by RNAi of PPARdelta.	Dopamine	40-48	peroxisome proliferator-activated receptor delta	Rattus norvegicus	106-115
23701913-10	2013	CONCLUSION: We suggest that dopamine can enhance cardiac contraction mainly through an activation of DA1 receptor-linked PLC pathway to increase cellular calcium ions for the increase of PPARdelta expression.	Dopamine	28-36	peroxisome proliferator-activated receptor delta	Rattus norvegicus	187-196
23701913-10	2013	CONCLUSION: We suggest that dopamine can enhance cardiac contraction mainly through an activation of DA1 receptor-linked PLC pathway to increase cellular calcium ions for the increase of PPARdelta expression.	Calcium	154-161	peroxisome proliferator-activated receptor delta	Rattus norvegicus	187-196
23752977-7	2013	The PPAR-beta antagonist GSK0660 prevented all vascular changes induced by GW0742 but not its antihypertensive effects.	GSK0660	25-32	peroxisome proliferator-activated receptor delta	Rattus norvegicus	4-13
23752977-7	2013	The PPAR-beta antagonist GSK0660 prevented all vascular changes induced by GW0742 but not its antihypertensive effects.	GW0742	75-81	peroxisome proliferator-activated receptor delta	Rattus norvegicus	4-13
23752977-8	2013	CONCLUSION: Vascular protective effects of GW0742 operate via PPAR-beta by interference with the ET-1 signalling as a result of increased expression of RGS5 and up-regulation of antioxidant genes and via PPAR-beta-independent mechanisms to decrease blood pressure.	GW0742	43-49	peroxisome proliferator-activated receptor delta	Rattus norvegicus	62-71
23752977-8	2013	CONCLUSION: Vascular protective effects of GW0742 operate via PPAR-beta by interference with the ET-1 signalling as a result of increased expression of RGS5 and up-regulation of antioxidant genes and via PPAR-beta-independent mechanisms to decrease blood pressure.	GW0742	43-49	peroxisome proliferator-activated receptor delta	Rattus norvegicus	204-213
23959725-0	2013	Liver X receptor agonist T0901317 enhanced peroxisome proliferator-activated receptor-delta expression and fatty acid oxidation in rat skeletal muscle.	T0901317	25-33	peroxisome proliferator-activated receptor delta	Rattus norvegicus	43-91
23959725-7	2013	T0901317 increased muscle expression of peroxisome proliferator-activated receptor-delta and its target genes involved in fatty acid uptake and oxidation.	Fatty Acids	122-132	peroxisome proliferator-activated receptor delta	Rattus norvegicus	40-88
23724037-4	2013	Thus, we used an agonist of PPARdelta, GW0742, to investigate this issue in the present study.	GW0742	39-45	peroxisome proliferator-activated receptor delta	Rattus norvegicus	28-37
23724037-6	2013	In diabetic rats with heart failure, GW0742 at a dose sufficient to activate PPARdelta reversed cardiac contraction without changes in heart rate.	GW0742	37-43	peroxisome proliferator-activated receptor delta	Rattus norvegicus	77-86
23724037-7	2013	In normal rats, PPARdelta enhanced cardiac contractility and hemodynamic dP/dtmax significantly more than dobutamine.	dp	73-75	peroxisome proliferator-activated receptor delta	Rattus norvegicus	16-25
23724037-7	2013	In normal rats, PPARdelta enhanced cardiac contractility and hemodynamic dP/dtmax significantly more than dobutamine.	dtmax	76-81	peroxisome proliferator-activated receptor delta	Rattus norvegicus	16-25
23724037-8	2013	Both actions were diminished by GSK0660 at a dose enough to block PPARdelta.	GSK0660	32-39	peroxisome proliferator-activated receptor delta	Rattus norvegicus	66-75
23724037-11	2013	CONCLUSION: Activation of PPARdelta by GW0742 increases cardiac contractility but not heart rate.	GW0742	39-45	peroxisome proliferator-activated receptor delta	Rattus norvegicus	26-35
23611928-1	2013	OBJECTIVES: This study aimed to measure the effects of peroxisome proliferator-activated receptor-delta (PPARdelta) agonist GW501516 (GW) and zinc sulfate (ZS) on ovariectomized rats" vaginal histomorphology and collagen expression.	GW 501516	124-132	peroxisome proliferator-activated receptor delta	Rattus norvegicus	55-103
23611928-1	2013	OBJECTIVES: This study aimed to measure the effects of peroxisome proliferator-activated receptor-delta (PPARdelta) agonist GW501516 (GW) and zinc sulfate (ZS) on ovariectomized rats" vaginal histomorphology and collagen expression.	GW 501516	124-132	peroxisome proliferator-activated receptor delta	Rattus norvegicus	105-114
23611928-1	2013	OBJECTIVES: This study aimed to measure the effects of peroxisome proliferator-activated receptor-delta (PPARdelta) agonist GW501516 (GW) and zinc sulfate (ZS) on ovariectomized rats" vaginal histomorphology and collagen expression.	GW 501516	124-126	peroxisome proliferator-activated receptor delta	Rattus norvegicus	55-103
23611928-1	2013	OBJECTIVES: This study aimed to measure the effects of peroxisome proliferator-activated receptor-delta (PPARdelta) agonist GW501516 (GW) and zinc sulfate (ZS) on ovariectomized rats" vaginal histomorphology and collagen expression.	GW 501516	124-126	peroxisome proliferator-activated receptor delta	Rattus norvegicus	105-114
23752977-1	2013	AIMS: We analysed the chronic effects of the peroxisome proliferator-activated receptor beta/delta (PPAR-beta) agonist GW0742 on the renin-independent hypertension induced by deoxycorticosterone acetate (DOCA)-salt.	GW0742	119-125	peroxisome proliferator-activated receptor delta	Rattus norvegicus	45-98
23752977-1	2013	AIMS: We analysed the chronic effects of the peroxisome proliferator-activated receptor beta/delta (PPAR-beta) agonist GW0742 on the renin-independent hypertension induced by deoxycorticosterone acetate (DOCA)-salt.	GW0742	119-125	peroxisome proliferator-activated receptor delta	Rattus norvegicus	100-109
23752977-1	2013	AIMS: We analysed the chronic effects of the peroxisome proliferator-activated receptor beta/delta (PPAR-beta) agonist GW0742 on the renin-independent hypertension induced by deoxycorticosterone acetate (DOCA)-salt.	Desoxycorticosterone Acetate	175-202	peroxisome proliferator-activated receptor delta	Rattus norvegicus	45-98
23752977-1	2013	AIMS: We analysed the chronic effects of the peroxisome proliferator-activated receptor beta/delta (PPAR-beta) agonist GW0742 on the renin-independent hypertension induced by deoxycorticosterone acetate (DOCA)-salt.	Desoxycorticosterone Acetate	175-202	peroxisome proliferator-activated receptor delta	Rattus norvegicus	100-109
23752977-1	2013	AIMS: We analysed the chronic effects of the peroxisome proliferator-activated receptor beta/delta (PPAR-beta) agonist GW0742 on the renin-independent hypertension induced by deoxycorticosterone acetate (DOCA)-salt.	Desoxycorticosterone Acetate	204-209	peroxisome proliferator-activated receptor delta	Rattus norvegicus	45-98
23752977-1	2013	AIMS: We analysed the chronic effects of the peroxisome proliferator-activated receptor beta/delta (PPAR-beta) agonist GW0742 on the renin-independent hypertension induced by deoxycorticosterone acetate (DOCA)-salt.	Desoxycorticosterone Acetate	204-209	peroxisome proliferator-activated receptor delta	Rattus norvegicus	100-109
23752977-1	2013	AIMS: We analysed the chronic effects of the peroxisome proliferator-activated receptor beta/delta (PPAR-beta) agonist GW0742 on the renin-independent hypertension induced by deoxycorticosterone acetate (DOCA)-salt.	Salts	210-214	peroxisome proliferator-activated receptor delta	Rattus norvegicus	45-98
23834779-0	2013	Enalaprilat increases PPARbeta/delta expression, without influence on PPARalpha and PPARgamma, and modulate cardiac function in sub-acute model of daunorubicin-induced cardiomyopathy.	Enalaprilat	0-11	peroxisome proliferator-activated receptor delta	Rattus norvegicus	22-30
23716627-2	2013	METHODS: HRMECs were treated with the PPAR-beta/delta agonist GW0742 and the antagonist GSK0660.	GW0742	62-68	peroxisome proliferator-activated receptor delta	Rattus norvegicus	38-47
23225238-0	2013	Increase of peroxisome proliferator-activated receptor delta (PPARdelta) by digoxin to improve lipid metabolism in the heart of diabetic rats.	Digoxin	76-83	peroxisome proliferator-activated receptor delta	Rattus norvegicus	62-71
23225238-1	2013	Increase of peroxisome proliferator-activated receptor delta (PPARdelta) expression by digoxin in the heart of diabetic rats has been documented.	Digoxin	87-94	peroxisome proliferator-activated receptor delta	Rattus norvegicus	12-60
23225238-1	2013	Increase of peroxisome proliferator-activated receptor delta (PPARdelta) expression by digoxin in the heart of diabetic rats has been documented.	Digoxin	87-94	peroxisome proliferator-activated receptor delta	Rattus norvegicus	62-71
23225238-2	2013	The present study investigated the mediation of PPARdelta in lipid metabolism improved by digoxin in the heart of diabetic rats and in the hyperglycemia-treated cardiomyocytes using the primary cultured cardiomyocytes from neonatal rat.	Digoxin	90-97	peroxisome proliferator-activated receptor delta	Rattus norvegicus	48-57
23225238-6	2013	After a 20-day digoxin treatment, the PPARdelta expression was elevated in hearts of diabetic rats while the cardiac lipid deposition was reduced.	Digoxin	15-22	peroxisome proliferator-activated receptor delta	Rattus norvegicus	38-47
23225238-7	2013	In neonatal cardiomyocytes, digoxin also caused an increase in expressions of PPARdelta and fatty acid oxidation genes.	Digoxin	28-35	peroxisome proliferator-activated receptor delta	Rattus norvegicus	78-87
23225238-8	2013	But both actions of digoxin were blocked by BAPTA-AM to chelate calcium ions and by siRNA-PPARdelta in cardiomyocytes.	Digoxin	20-27	peroxisome proliferator-activated receptor delta	Rattus norvegicus	90-99
23225238-9	2013	The obtained results show that increase of PPARdelta by digoxin is related to regulation of fatty acid oxidation genes in cardiac cells mediated by calcium-triggered signals.	Digoxin	56-63	peroxisome proliferator-activated receptor delta	Rattus norvegicus	43-52
23225238-9	2013	The obtained results show that increase of PPARdelta by digoxin is related to regulation of fatty acid oxidation genes in cardiac cells mediated by calcium-triggered signals.	Fatty Acids	92-102	peroxisome proliferator-activated receptor delta	Rattus norvegicus	43-52
23225238-9	2013	The obtained results show that increase of PPARdelta by digoxin is related to regulation of fatty acid oxidation genes in cardiac cells mediated by calcium-triggered signals.	Calcium	148-155	peroxisome proliferator-activated receptor delta	Rattus norvegicus	43-52
23256146-6	2013	These niacin-induced changes in muscle metabolic phenotype are indicative of an increased capacity of muscle for oxidative utilization of fatty acids and are likely mediated by the upregulation of Ppard, Ppargc1a, and Ppargc1b, which are key regulators of muscle fiber composition, mitochondrial biogenesis, angiogenesis, and genes involved in fatty acid catabolism and oxidative phosphorylation.	Niacin	6-12	peroxisome proliferator-activated receptor delta	Rattus norvegicus	197-202
23833373-1	2013	OBJECTIVE: In this study, we investigated the role of peroxisome proliferator-activated receptors (PPAR)-beta/delta receptors in carrageenan-induced inflammation and in the anti-inflammatory effects of all-trans retinoic acid (ATRA).	Carrageenan	129-140	peroxisome proliferator-activated receptor delta	Rattus norvegicus	99-109
23833373-8	2013	Treatment with ATRA (5 mg/kg/p.o/4 days) and GW0742, a selective PPAR-beta/delta receptor agonist (0.1 mg/kg/i.p/4 days), significantly decreased the paw volume, mechanical and TH as compared to vehicle control.	Tretinoin	15-19	peroxisome proliferator-activated receptor delta	Rattus norvegicus	65-74
23833373-8	2013	Treatment with ATRA (5 mg/kg/p.o/4 days) and GW0742, a selective PPAR-beta/delta receptor agonist (0.1 mg/kg/i.p/4 days), significantly decreased the paw volume, mechanical and TH as compared to vehicle control.	GW0742	45-51	peroxisome proliferator-activated receptor delta	Rattus norvegicus	65-74
23833373-12	2013	CONCLUSION: From above findings, it can be concluded that ATRA exerts anti-inflammatory and anti-hyperalgesic effect, possibly through activation of PPAR-beta/delta and subsequent reduction of oxido-nitrosative stress.	Tretinoin	58-62	peroxisome proliferator-activated receptor delta	Rattus norvegicus	149-158
22683600-2	2012	Herein, we have analyzed if the peroxisome proliferator-activated receptor-beta/-delta (PPARbeta/delta) agonist GW0742 exerts protective effects on endothelial function in type 1 diabetic rats.	GW0742	112-118	peroxisome proliferator-activated receptor delta	Rattus norvegicus	32-86
22988930-0	2013	Chronic alcohol-induced hepatic insulin resistance and endoplasmic reticulum stress ameliorated by peroxisome-proliferator activated receptor-delta agonist treatment.	Alcohols	8-15	peroxisome proliferator-activated receptor delta	Rattus norvegicus	99-147
23555761-5	2013	Treatment of myotubes with dexamethasone increased PPARbeta/delta expression and activity.	Dexamethasone	27-40	peroxisome proliferator-activated receptor delta	Rattus norvegicus	51-59
23555761-6	2013	Dexamethasone-induced FOXO1 activation and atrogin-1 and MuRF1 expression, protein degradation, and myotube atrophy were inhibited by PPARbeta/delta blocker or siRNA.	Dexamethasone	0-13	peroxisome proliferator-activated receptor delta	Rattus norvegicus	134-142
23555761-7	2013	Importantly, muscle wasting induced in rats by dexamethasone or sepsis was prevented by treatment with a PPARbeta/delta inhibitor.	Dexamethasone	47-60	peroxisome proliferator-activated receptor delta	Rattus norvegicus	105-113
23533379-0	2013	Doxorubicin-Induced Cardiac Toxicity Is Mediated by Lowering of Peroxisome Proliferator-Activated Receptor delta Expression in Rats.	Doxorubicin	0-11	peroxisome proliferator-activated receptor delta	Rattus norvegicus	64-112
22683600-2	2012	Herein, we have analyzed if the peroxisome proliferator-activated receptor-beta/-delta (PPARbeta/delta) agonist GW0742 exerts protective effects on endothelial function in type 1 diabetic rats.	GW0742	112-118	peroxisome proliferator-activated receptor delta	Rattus norvegicus	88-96
22683600-8	2012	In addition, GW0742 prevented the endothelial dysfunction and the upregulation of prepro endothelin-1 and p47(phox) after the in vitro incubation of aortic rings with high glucose and these effects were prevented by the PPARbeta/delta antagonist GSK0660.	GW0742	13-19	peroxisome proliferator-activated receptor delta	Rattus norvegicus	220-228
21825230-2	2011	We studied whether the PPARbeta agonist GW0742 might exert antihypertensive effects in spontaneously hypertensive rats (SHRs).	GW0742	40-46	peroxisome proliferator-activated receptor delta	Rattus norvegicus	23-31
22183794-9	2012	In addition, the up-regulated inflammation factors such as TNF-alpha and IL-6, and the down-regulated PPAR alpha and PPAR beta were normalizd by PMQ treatment.	pmq	145-148	peroxisome proliferator-activated receptor delta	Rattus norvegicus	117-126
22183794-10	2012	CONCLUSION: PMQ has significant protective effects on cardiac hypertrophy through up-regulating the mRNA and protein levels of PPAR alpha and PPAR beta involved in the process of inflammation response and cardiac fibrosis.	pmq	12-15	peroxisome proliferator-activated receptor delta	Rattus norvegicus	142-151
21896929-0	2011	Role of lipid peroxidation and PPAR-delta in amplifying glucose-stimulated insulin secretion.	Glucose	56-63	peroxisome proliferator-activated receptor delta	Rattus norvegicus	31-41
21896929-9	2011	The latter mimicked the GSIS-amplifying effect of high glucose preexposure and of the PPAR-delta agonist GW501516 in INS-1E cells and isolated rat islets.	GW 501516	105-113	peroxisome proliferator-activated receptor delta	Rattus norvegicus	86-96
21896929-10	2011	These effects were blocked with GSK0660, a selective PPAR-delta antagonist, and the antioxidant N-acetylcysteine or by silencing PPAR-delta expression.	GSK0660	32-39	peroxisome proliferator-activated receptor delta	Rattus norvegicus	53-63
21896929-11	2011	High glucose, 4-HNE, and GW501516 also induced luciferase expression in a PPAR-delta-mediated transactivation assay.	Glucose	5-12	peroxisome proliferator-activated receptor delta	Rattus norvegicus	74-84
21896929-11	2011	High glucose, 4-HNE, and GW501516 also induced luciferase expression in a PPAR-delta-mediated transactivation assay.	4-hydroxy-2-nonenal	14-19	peroxisome proliferator-activated receptor delta	Rattus norvegicus	74-84
21896929-11	2011	High glucose, 4-HNE, and GW501516 also induced luciferase expression in a PPAR-delta-mediated transactivation assay.	GW 501516	25-33	peroxisome proliferator-activated receptor delta	Rattus norvegicus	74-84
19997057-13	2010	Thus, immediate administration of the PPAR-beta/delta ligand GW0742 during reperfusion reduces myocardial infarct size in the rat by a mechanism that may involve inhibition of the activity of glycogen synthase kinase-3beta secondary to activation of the Akt pathway.	GW0742	61-67	peroxisome proliferator-activated receptor delta	Rattus norvegicus	38-47
21047550-6	2011	Administration of the selective PPARbeta/delta agonist GW0742 attenuated the renal dysfunction, leukocyte infiltration, and formation of interleukin-6 and tumor necrosis factor-alpha.	GW0742	55-61	peroxisome proliferator-activated receptor delta	Rattus norvegicus	32-40
21047550-8	2011	The beneficial effects of GW0742 were attenuated by the selective PPARbeta/delta antagonist GSK0660.	GW0742	26-32	peroxisome proliferator-activated receptor delta	Rattus norvegicus	66-74
21047550-8	2011	The beneficial effects of GW0742 were attenuated by the selective PPARbeta/delta antagonist GSK0660.	GSK0660	92-99	peroxisome proliferator-activated receptor delta	Rattus norvegicus	66-74
19660859-4	2010	Inhibition of C20 cell proliferation and clonogenicity was observed following treatment with GW0742 or GW501516, two highly specific PPARbeta/delta ligands.	GW0742	93-99	peroxisome proliferator-activated receptor delta	Rattus norvegicus	133-141
20410836-9	2010	In primary cortical neurones, pioglitazone stimulated the IL-1ra production via activation of the PPARbeta/delta, but prevented excitotoxic neuronal injury and death by a PPARgamma-dependent mechanism.	Pioglitazone	30-42	peroxisome proliferator-activated receptor delta	Rattus norvegicus	98-106
20410836-10	2010	CONCLUSION: Our data demonstrate that activation of PPARgamma and PPAR beta/delta by proglitazone in neurones triggers diverse neuroprotective mechanisms.	proglitazone	85-97	peroxisome proliferator-activated receptor delta	Rattus norvegicus	66-75
20209098-0	2010	The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension.	GW0742	27-33	peroxisome proliferator-activated receptor delta	Rattus norvegicus	4-12
20209098-6	2010	METHODOLOGY/PRINCIPAL FINDINGS: Here we show that the PPARbeta/delta agonist GW0742 induces vasorelaxation in systemic and pulmonary vessels.	GW0742	77-83	peroxisome proliferator-activated receptor delta	Rattus norvegicus	54-62
19965574-0	2010	PPARdelta is a fatty acid sensor that enhances mitochondrial oxidation in insulin-secreting cells and protects against fatty acid-induced dysfunction.	Fatty Acids	15-25	peroxisome proliferator-activated receptor delta	Rattus norvegicus	0-9
19965574-0	2010	PPARdelta is a fatty acid sensor that enhances mitochondrial oxidation in insulin-secreting cells and protects against fatty acid-induced dysfunction.	Fatty Acids	119-129	peroxisome proliferator-activated receptor delta	Rattus norvegicus	0-9
19965574-4	2010	Interestingly, unsaturated fatty acids mimic the effects of synthetic PPARdelta agonists.	Fatty Acids, Unsaturated	15-38	peroxisome proliferator-activated receptor delta	Rattus norvegicus	70-79
19965574-5	2010	Using short hairpin RNA-mediated knockdown, we demonstrate that the ability of unsaturated fatty acids to stimulate fatty acid metabolism is dependent on PPARdelta.	Fatty Acids, Unsaturated	79-102	peroxisome proliferator-activated receptor delta	Rattus norvegicus	154-163
19965574-5	2010	Using short hairpin RNA-mediated knockdown, we demonstrate that the ability of unsaturated fatty acids to stimulate fatty acid metabolism is dependent on PPARdelta.	Fatty Acids	91-101	peroxisome proliferator-activated receptor delta	Rattus norvegicus	154-163
19965574-6	2010	Activation of PPARdelta increases the fatty acid oxidation capacity in INS-1E beta-cells, enhances glucose-stimulated insulin secretion (GSIS) from islets, and protects GSIS against adverse effects of prolonged fatty acid exposure.	Fatty Acids	38-48	peroxisome proliferator-activated receptor delta	Rattus norvegicus	14-23
19965574-6	2010	Activation of PPARdelta increases the fatty acid oxidation capacity in INS-1E beta-cells, enhances glucose-stimulated insulin secretion (GSIS) from islets, and protects GSIS against adverse effects of prolonged fatty acid exposure.	Glucose	99-106	peroxisome proliferator-activated receptor delta	Rattus norvegicus	14-23
19965574-6	2010	Activation of PPARdelta increases the fatty acid oxidation capacity in INS-1E beta-cells, enhances glucose-stimulated insulin secretion (GSIS) from islets, and protects GSIS against adverse effects of prolonged fatty acid exposure.	Fatty Acids	211-221	peroxisome proliferator-activated receptor delta	Rattus norvegicus	14-23
19965574-7	2010	The presented results indicate that the nuclear receptor PPARdelta is a fatty acid sensor that adapts beta-cell mitochondrial function to long-term changes in unsaturated fatty acid levels.	Fatty Acids	72-82	peroxisome proliferator-activated receptor delta	Rattus norvegicus	57-66
19965574-7	2010	The presented results indicate that the nuclear receptor PPARdelta is a fatty acid sensor that adapts beta-cell mitochondrial function to long-term changes in unsaturated fatty acid levels.	Fatty Acids, Unsaturated	159-181	peroxisome proliferator-activated receptor delta	Rattus norvegicus	57-66
19660859-4	2010	Inhibition of C20 cell proliferation and clonogenicity was observed following treatment with GW0742 or GW501516, two highly specific PPARbeta/delta ligands.	GW 501516	103-111	peroxisome proliferator-activated receptor delta	Rattus norvegicus	133-141
19422681-0	2009	Effects of the PPAR-beta agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination.	GW 501516	33-41	peroxisome proliferator-activated receptor delta	Rattus norvegicus	15-24
19483106-8	2009	However, the addition of L-165041 potentiated the effect of PPARgamma activation through PPARbeta/delta-dependent mechanism.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	25-33	peroxisome proliferator-activated receptor delta	Rattus norvegicus	89-97
19859757-2	2009	In this work, supplementing primary cultures of neonatal rat cardiomyocytes with 60 microM EPA or DHA, we demonstrated by an ELISA assay an increased PPAR beta/delta binding to DNA.	dehydroacetic acid	98-101	peroxisome proliferator-activated receptor delta	Rattus norvegicus	150-159
19422681-7	2009	GW 501516, a specific PPAR-beta agonist, was examined for its capacity to protect from antibody-mediated demyelination and to prevent inflammatory responses induced by IFN-gamma and LPS.	GW 501516	0-9	peroxisome proliferator-activated receptor delta	Rattus norvegicus	22-31
19422681-11	2009	RESULTS: GW 501516 decreased the IFN-gamma-induced up-regulation of TNF-alpha and iNOS in accord with the proposed anti-inflammatory effects of this PPAR-beta agonist.	GW 501516	9-18	peroxisome proliferator-activated receptor delta	Rattus norvegicus	149-158
18573863-0	2008	Decrease of peroxisome proliferator-activated receptor delta expression in cardiomyopathy of streptozotocin-induced diabetic rats.	Streptozocin	93-107	peroxisome proliferator-activated receptor delta	Rattus norvegicus	12-60
19131364-8	2009	Activation of peroxisome proliferator-activated receptor-alpha (PPARalpha) and PPARbeta/delta counteracted Ang II-mediated reduction of the fatty acid oxidation pathway.	Fatty Acids	140-150	peroxisome proliferator-activated receptor delta	Rattus norvegicus	79-87
19237170-14	2009	Concomitant administration of GW9662 reversed the protection exerted by PPARbeta/delta agonist.	2-chloro-5-nitrobenzanilide	30-36	peroxisome proliferator-activated receptor delta	Rattus norvegicus	72-80
19065603-12	2009	Moreover, treatment with either pioglitazone or exenatide restored and increased the expression of PPAR beta/delta in non-diabetic Wistar islets.	Pioglitazone	32-44	peroxisome proliferator-activated receptor delta	Rattus norvegicus	99-108
19065603-12	2009	Moreover, treatment with either pioglitazone or exenatide restored and increased the expression of PPAR beta/delta in non-diabetic Wistar islets.	Exenatide	48-57	peroxisome proliferator-activated receptor delta	Rattus norvegicus	99-108
18573863-3	2008	METHODS AND RESULTS: We used male Wistar rats to examine the effect of hyperglycaemia on PPARdelta expression in streptozotocin-induced diabetic rats, primary neonatal rat cardiomyocytes, and H9c2 embryonic rat cardiomyocytes.	Streptozocin	113-127	peroxisome proliferator-activated receptor delta	Rattus norvegicus	89-98
18573863-8	2008	Cardiomyopathy induced in streptozotocin-diabetic rats was associated with a marked decrease in cardiac PPARdelta expression.	Streptozocin	26-40	peroxisome proliferator-activated receptor delta	Rattus norvegicus	104-113
18573863-11	2008	CONCLUSION: Our results suggest that inhibitors of ROS production or MAPK activation are involved in reduction of cardiac PPARdelta expression in response to hyperglycaemia.	Reactive Oxygen Species	51-54	peroxisome proliferator-activated receptor delta	Rattus norvegicus	122-131
18063688-6	2008	Treatment of cardiomyocytes with ciglitazone, a PPARgamma agonist, or 9-cis retinoic acid (RA), a RXR agonist, increased insulin- and metabolic stress-stimulated glucose transport, whereas agonists of PPARalpha or PPARbeta/delta had no effect.	ciglitazone	33-44	peroxisome proliferator-activated receptor delta	Rattus norvegicus	214-222
18443198-3	2008	RESEARCH DESIGN AND METHODS AND RESULTS: First, we examined whether the PPARbeta/delta agonist GW501516 prevents lipopolysaccharide (LPS)-induced cytokine production in differentiated 3T3-L1 adipocytes.	GW 501516	95-103	peroxisome proliferator-activated receptor delta	Rattus norvegicus	72-80
18591261-10	2008	Related changes in the skeletal muscle Slc2a4, Ucp3, and Ppard indicate that fetal glucocorticoid excess disturbs adult glucose/fatty acid transport and metabolism.	Glucose	120-127	peroxisome proliferator-activated receptor delta	Rattus norvegicus	57-62
18591261-10	2008	Related changes in the skeletal muscle Slc2a4, Ucp3, and Ppard indicate that fetal glucocorticoid excess disturbs adult glucose/fatty acid transport and metabolism.	Fatty Acids	128-138	peroxisome proliferator-activated receptor delta	Rattus norvegicus	57-62
18063688-6	2008	Treatment of cardiomyocytes with ciglitazone, a PPARgamma agonist, or 9-cis retinoic acid (RA), a RXR agonist, increased insulin- and metabolic stress-stimulated glucose transport, whereas agonists of PPARalpha or PPARbeta/delta had no effect.	Alitretinoin	70-89	peroxisome proliferator-activated receptor delta	Rattus norvegicus	214-222
18063688-6	2008	Treatment of cardiomyocytes with ciglitazone, a PPARgamma agonist, or 9-cis retinoic acid (RA), a RXR agonist, increased insulin- and metabolic stress-stimulated glucose transport, whereas agonists of PPARalpha or PPARbeta/delta had no effect.	Tretinoin	91-93	peroxisome proliferator-activated receptor delta	Rattus norvegicus	214-222
17620284-3	2008	Beraprost eliminated increases in proliferation of rat aortic smooth muscle cells (RASMCs) by 12-O-tetradecanoylphorbol 13-acetate, and enhanced the peroxisome proliferator-activated receptor-delta (PPARdelta) and inducible nitric oxide synthetase (iNOS) expressions, which were associated with the antiproliferative action of beraprost according to inhibition experiments by [(3)H]thymidine incorporation.	Thymidine	382-391	peroxisome proliferator-activated receptor delta	Rattus norvegicus	199-208
18293166-5	2008	For the examination of PPAR beta/delta effect, the cultured rat cardiac myocytes were pretreated with GW0742 (10 micromol.L(-1)), an agonist of PPARbeta/delta, for 48h before Ang II stimulation.	GW0742	102-108	peroxisome proliferator-activated receptor delta	Rattus norvegicus	144-152
17854349-0	2007	Neuroprotective actions of noradrenaline: effects on glutathione synthesis and activation of peroxisome proliferator activated receptor delta.	Norepinephrine	27-40	peroxisome proliferator-activated receptor delta	Rattus norvegicus	93-141
17726146-1	2007	Peroxisome proliferator-activated receptor-delta (PPARdelta) activation results in upregulation of genes associated with skeletal muscle fatty acid oxidation and mitochondrial uncoupling.	Fatty Acids	137-147	peroxisome proliferator-activated receptor delta	Rattus norvegicus	0-48
17908795-10	2007	The knockdown of BCL-6 by short interfering RNA abolished the inhibitory effect of the PPARbeta ligand on sPLA2 activity and prostaglandin E2 release.	Dinoprostone	125-141	peroxisome proliferator-activated receptor delta	Rattus norvegicus	87-95
17643263-8	2007	Selective activation of either PPARalpha or PPARbeta/delta completely restored expression of regulatory genes of fatty acid metabolism but did not influence cardiac myocyte size and markers of hypertrophy.	Fatty Acids	113-123	peroxisome proliferator-activated receptor delta	Rattus norvegicus	44-52
17643263-11	2007	Inactivation of PPARalpha and PPARbeta/delta accounts for downregulation of the fatty acid oxidation pathway, whereas inactivation of PPARgamma enables development of hypertrophy.	Fatty Acids	80-90	peroxisome proliferator-activated receptor delta	Rattus norvegicus	30-38
17726146-1	2007	Peroxisome proliferator-activated receptor-delta (PPARdelta) activation results in upregulation of genes associated with skeletal muscle fatty acid oxidation and mitochondrial uncoupling.	Fatty Acids	137-147	peroxisome proliferator-activated receptor delta	Rattus norvegicus	50-59
17726146-3	2007	Therefore, in this study we examined the response of a selective PPARdelta agonist (GW610742X at 5 or 100 mg.kg(-1).day(-1) for 8 days) on skeletal-muscle lipid metabolism and mitochondrial coupling efficiency in rats by using in vivo magnetic resonance spectroscopy (MRS).	gw610742x	84-93	peroxisome proliferator-activated receptor delta	Rattus norvegicus	65-74
17726146-10	2007	In summary, these are the first noninvasive measurements illustrating a selective PPARdelta-mediated decrease in muscle lipid content that was consistent with a shift in metabolic substrate utilization from carbohydrate to lipid.	Carbohydrates	207-219	peroxisome proliferator-activated receptor delta	Rattus norvegicus	82-91
17346664-4	2007	GW501516, a selective PPARbeta/delta agonist, depressed Ang II-stimulated collagen type I expression and collagen synthesis in cardiac fibroblasts in a concentration-dependent manner.	GW 501516	0-8	peroxisome proliferator-activated receptor delta	Rattus norvegicus	22-30
17869249-0	2007	The PPARdelta agonist, GW501516, promotes fatty acid oxidation but has no direct effect on glucose utilisation or insulin sensitivity in rat L6 skeletal muscle cells.	GW 501516	23-31	peroxisome proliferator-activated receptor delta	Rattus norvegicus	4-13
17869249-0	2007	The PPARdelta agonist, GW501516, promotes fatty acid oxidation but has no direct effect on glucose utilisation or insulin sensitivity in rat L6 skeletal muscle cells.	Fatty Acids	42-52	peroxisome proliferator-activated receptor delta	Rattus norvegicus	4-13
17869249-1	2007	Peroxisome proliferator-activated receptor-delta (PPARdelta) activation enhances skeletal muscle fatty acid oxidation and improves whole body glucose homeostasis and insulin sensitivity.	Fatty Acids	97-107	peroxisome proliferator-activated receptor delta	Rattus norvegicus	0-48
17869249-1	2007	Peroxisome proliferator-activated receptor-delta (PPARdelta) activation enhances skeletal muscle fatty acid oxidation and improves whole body glucose homeostasis and insulin sensitivity.	Fatty Acids	97-107	peroxisome proliferator-activated receptor delta	Rattus norvegicus	50-59
17869249-4	2007	Our findings exclude sarcolemmal glucose transport as a potential target for the therapeutic action of PPARdelta agonists in skeletal muscle.	Glucose	33-40	peroxisome proliferator-activated receptor delta	Rattus norvegicus	103-112
17478558-5	2007	Within 8 h of single-dose T(3) administration, hypothyroid rats showed a rise in serum fatty acid levels concomitant with a rapid increase in UCP3 expression in gastrocnemius muscle, followed by inductions of peroxisome proliferator activated receptor delta (PPARdelta) (within 24 h) and PPAR target gene expression (after 24 h).	Triiodothyronine	26-30	peroxisome proliferator-activated receptor delta	Rattus norvegicus	209-257
17478558-5	2007	Within 8 h of single-dose T(3) administration, hypothyroid rats showed a rise in serum fatty acid levels concomitant with a rapid increase in UCP3 expression in gastrocnemius muscle, followed by inductions of peroxisome proliferator activated receptor delta (PPARdelta) (within 24 h) and PPAR target gene expression (after 24 h).	Triiodothyronine	26-30	peroxisome proliferator-activated receptor delta	Rattus norvegicus	259-268
17959046-6	2007	Moreover, peroxisome proliferator-activated receptors (PPARs), as important nuclear receptor genes of relating lipid metabolism, the expressions of PPARbeta and PPARgamma mRNA were significantly up-regulated in mammary adipose tissues of MNU-induced breast cancer as compared with the control groups, but the expression levels of peroxisome proliferator-activated receptors (PPARs) in rats fed with 1:1 n-6/n-3 group were lowest (P < 0.05).	Methylnitrosourea	238-241	peroxisome proliferator-activated receptor delta	Rattus norvegicus	148-156
17478558-6	2007	This T(3)-induced early UCP3 expression depended on fatty acid-PPAR signaling because depleting serum fatty acid levels abolished its expression, restorable by administration of the PPARdelta agonist L165,041 (4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]acetic acid).	Triiodothyronine	5-9	peroxisome proliferator-activated receptor delta	Rattus norvegicus	182-191
17478558-6	2007	This T(3)-induced early UCP3 expression depended on fatty acid-PPAR signaling because depleting serum fatty acid levels abolished its expression, restorable by administration of the PPARdelta agonist L165,041 (4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]acetic acid).	Fatty Acids	52-62	peroxisome proliferator-activated receptor delta	Rattus norvegicus	182-191
17478558-6	2007	This T(3)-induced early UCP3 expression depended on fatty acid-PPAR signaling because depleting serum fatty acid levels abolished its expression, restorable by administration of the PPARdelta agonist L165,041 (4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]acetic acid).	l165,041	200-208	peroxisome proliferator-activated receptor delta	Rattus norvegicus	182-191
17478558-6	2007	This T(3)-induced early UCP3 expression depended on fatty acid-PPAR signaling because depleting serum fatty acid levels abolished its expression, restorable by administration of the PPARdelta agonist L165,041 (4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]acetic acid).	4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]acetic acid	210-278	peroxisome proliferator-activated receptor delta	Rattus norvegicus	182-191
17666912-3	2007	PPARdelta-specific agonist treatment (GW610742X at 30 and 100 mg/kg/day for 6-9 weeks) was initiated immediately postmyocardial infarction (MI) in Sprague-Dawley rats.	gw610742x	38-47	peroxisome proliferator-activated receptor delta	Rattus norvegicus	0-9
17346664-5	2007	Furthermore, these inhibitory effects of GW501516 were completely reversed by the knockdown of PPARbeta/delta via RNA interference.	GW 501516	41-49	peroxisome proliferator-activated receptor delta	Rattus norvegicus	95-103
16337160-5	2006	By performing cell viability assays, we also showed that the selective PPARdelta agonist GW501516 protected cells from H(2)O(2)-induced cell death.	GW 501516	89-97	peroxisome proliferator-activated receptor delta	Rattus norvegicus	71-80
17148578-5	2007	In embryos from control rats, the addition of the PPARdelta activators (cPGI(2) and PGA(1)) increased embryonic phospholipid levels and de novo phospholipid synthesis studied using (14)C-acetate as a tracer.	Phospholipids	112-124	peroxisome proliferator-activated receptor delta	Rattus norvegicus	50-59
17148578-5	2007	In embryos from control rats, the addition of the PPARdelta activators (cPGI(2) and PGA(1)) increased embryonic phospholipid levels and de novo phospholipid synthesis studied using (14)C-acetate as a tracer.	Phospholipids	144-156	peroxisome proliferator-activated receptor delta	Rattus norvegicus	50-59
17148578-5	2007	In embryos from control rats, the addition of the PPARdelta activators (cPGI(2) and PGA(1)) increased embryonic phospholipid levels and de novo phospholipid synthesis studied using (14)C-acetate as a tracer.	c-acetate	185-194	peroxisome proliferator-activated receptor delta	Rattus norvegicus	50-59
17148578-6	2007	PGE(2) formed from arachidonate released from phospholipid stores was also up-regulated by PPARdelta activators.	Dinoprostone	0-6	peroxisome proliferator-activated receptor delta	Rattus norvegicus	91-100
17148578-6	2007	PGE(2) formed from arachidonate released from phospholipid stores was also up-regulated by PPARdelta activators.	Arachidonic Acid	19-31	peroxisome proliferator-activated receptor delta	Rattus norvegicus	91-100
17148578-6	2007	PGE(2) formed from arachidonate released from phospholipid stores was also up-regulated by PPARdelta activators.	Phospholipids	46-58	peroxisome proliferator-activated receptor delta	Rattus norvegicus	91-100
16406631-0	2007	Increase of peroxisome proliferator-activated receptor delta gene expression in the lungs of streptozotocin-induced diabetic rats.	Streptozocin	93-107	peroxisome proliferator-activated receptor delta	Rattus norvegicus	12-60
17148578-8	2007	These data suggest that PPARdelta may play an important role in lipid metabolic and signalling pathways during embryo organogenesis, developmental pathways that are altered in embryos from diabetic rats, possibly as a result of a reduction in levels of PPARdelta and its endogenous activator PGI(2).	Prostaglandins I	292-295	peroxisome proliferator-activated receptor delta	Rattus norvegicus	24-33
17148578-8	2007	These data suggest that PPARdelta may play an important role in lipid metabolic and signalling pathways during embryo organogenesis, developmental pathways that are altered in embryos from diabetic rats, possibly as a result of a reduction in levels of PPARdelta and its endogenous activator PGI(2).	Prostaglandins I	292-295	peroxisome proliferator-activated receptor delta	Rattus norvegicus	253-262
16960684-0	2006	Activation of PPAR-delta in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids.	Glucose	87-94	peroxisome proliferator-activated receptor delta	Rattus norvegicus	14-24
16960684-0	2006	Activation of PPAR-delta in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids.	Fatty Acids	98-109	peroxisome proliferator-activated receptor delta	Rattus norvegicus	14-24
16960684-1	2006	AIMS/HYPOTHESIS: GW501516, an agonist of peroxisome proliferator-activated receptor-delta (PPAR-delta), increases lipid combustion and exerts antidiabetic action in animals, effects which are attributed mainly to direct effects on skeletal muscle.	GW 501516	17-25	peroxisome proliferator-activated receptor delta	Rattus norvegicus	41-89
16960684-1	2006	AIMS/HYPOTHESIS: GW501516, an agonist of peroxisome proliferator-activated receptor-delta (PPAR-delta), increases lipid combustion and exerts antidiabetic action in animals, effects which are attributed mainly to direct effects on skeletal muscle.	GW 501516	17-25	peroxisome proliferator-activated receptor delta	Rattus norvegicus	91-101
16960684-9	2006	CONCLUSIONS/INTERPRETATION: GW501516-induced activation of PPAR-delta reduces glucose utilisation by skeletal muscle through a switch in mitochondrial substrate preference from carbohydrate to lipid.	GW 501516	28-36	peroxisome proliferator-activated receptor delta	Rattus norvegicus	59-69
16960684-9	2006	CONCLUSIONS/INTERPRETATION: GW501516-induced activation of PPAR-delta reduces glucose utilisation by skeletal muscle through a switch in mitochondrial substrate preference from carbohydrate to lipid.	Glucose	78-85	peroxisome proliferator-activated receptor delta	Rattus norvegicus	59-69
16960684-9	2006	CONCLUSIONS/INTERPRETATION: GW501516-induced activation of PPAR-delta reduces glucose utilisation by skeletal muscle through a switch in mitochondrial substrate preference from carbohydrate to lipid.	Carbohydrates	177-189	peroxisome proliferator-activated receptor delta	Rattus norvegicus	59-69
16731579-2	2006	Due to its fatty acid structure, PFOA may activate other NRs, such as PPARbeta, PPARgamma, liver X receptor (LXR), or retinoid X receptor (RXR).	perfluorooctanoic acid	33-37	peroxisome proliferator-activated receptor delta	Rattus norvegicus	70-78
16731579-3	2006	In this study, the activation of human, mouse, and rat PPARalpha, PPARbeta, PPARgamma, LXRbeta, and RXRalpha by PFOA (including its linear and branched isomers) and perfluorooctane sulfonate (PFOS) was investigated and compared to several structural classes of natural fatty acids and appropriate positive control ligands.	perfluorooctanoic acid	112-116	peroxisome proliferator-activated receptor delta	Rattus norvegicus	66-74
16337160-5	2006	By performing cell viability assays, we also showed that the selective PPARdelta agonist GW501516 protected cells from H(2)O(2)-induced cell death.	Hydrogen Peroxide	119-127	peroxisome proliferator-activated receptor delta	Rattus norvegicus	71-80
16337160-7	2006	We demonstrated by transient transfection of a dominant negative mutant of PPARdelta that the protection induced by GW501516 was totally dependent on PPARdelta.	GW 501516	116-124	peroxisome proliferator-activated receptor delta	Rattus norvegicus	75-84
16337160-7	2006	We demonstrated by transient transfection of a dominant negative mutant of PPARdelta that the protection induced by GW501516 was totally dependent on PPARdelta.	GW 501516	116-124	peroxisome proliferator-activated receptor delta	Rattus norvegicus	150-159
16077083-3	2006	TG accumulation resulted from enhanced macropinocytosis and decreased efflux secondary to a 40-50% reduction in peroxisome proliferator-activated receptor (PPAR)-delta (PPARdelta).	Triglycerides	0-2	peroxisome proliferator-activated receptor delta	Rattus norvegicus	112-167
15211590-2	2004	We sought to examine the role of PPARbeta in neuronal cell death by using the PPARbeta ligand GW0742.	GW0742	94-100	peroxisome proliferator-activated receptor delta	Rattus norvegicus	78-86
16139565-3	2005	Embryonic rat heart-derived H9c2 cells stimulated with lipopolysaccharide (LPS) showed a reduction (38%, P<0.05) in the mRNA levels of the PPARbeta/delta-target gene pyruvatedehydrogenase kinase 4 (PDK4) that was prevented in the presence of the NF-kappaB inhibitors parthenolide (10 microM) and atorvastatin (10 microM).	pyruvatedehydrogenase	169-190	peroxisome proliferator-activated receptor delta	Rattus norvegicus	142-150
16139565-3	2005	Embryonic rat heart-derived H9c2 cells stimulated with lipopolysaccharide (LPS) showed a reduction (38%, P<0.05) in the mRNA levels of the PPARbeta/delta-target gene pyruvatedehydrogenase kinase 4 (PDK4) that was prevented in the presence of the NF-kappaB inhibitors parthenolide (10 microM) and atorvastatin (10 microM).	parthenolide	270-282	peroxisome proliferator-activated receptor delta	Rattus norvegicus	142-150
16139565-3	2005	Embryonic rat heart-derived H9c2 cells stimulated with lipopolysaccharide (LPS) showed a reduction (38%, P<0.05) in the mRNA levels of the PPARbeta/delta-target gene pyruvatedehydrogenase kinase 4 (PDK4) that was prevented in the presence of the NF-kappaB inhibitors parthenolide (10 microM) and atorvastatin (10 microM).	Atorvastatin	299-311	peroxisome proliferator-activated receptor delta	Rattus norvegicus	142-150
16139565-7	2005	Co-immunoprecipitation studies showed that LPS-stimulation led to a reduction in the physical interaction between PGC-1 and PPARbeta/delta and that this reduction was prevented in the presence of atorvastatin.	Atorvastatin	196-208	peroxisome proliferator-activated receptor delta	Rattus norvegicus	124-132
16139565-8	2005	Finally, electrophoretic mobility shift assay revealed that parthenolide and atorvastatin prevented LPS-mediated reduction in PPARbeta/delta binding activity in H9c2 cardiac cells.	parthenolide	60-72	peroxisome proliferator-activated receptor delta	Rattus norvegicus	126-134
16139565-8	2005	Finally, electrophoretic mobility shift assay revealed that parthenolide and atorvastatin prevented LPS-mediated reduction in PPARbeta/delta binding activity in H9c2 cardiac cells.	Atorvastatin	77-89	peroxisome proliferator-activated receptor delta	Rattus norvegicus	126-134
16139565-9	2005	These results suggest that LPS-mediated NF-kappaB activation inhibits the expression of genes involved in fatty acid metabolism by a mechanism involving reduced expression of PGC-1, which in turn affects the PPARbeta/delta transactivation of target genes involved in cardiac fatty acid oxidation.	Fatty Acids	106-116	peroxisome proliferator-activated receptor delta	Rattus norvegicus	208-216
16139565-9	2005	These results suggest that LPS-mediated NF-kappaB activation inhibits the expression of genes involved in fatty acid metabolism by a mechanism involving reduced expression of PGC-1, which in turn affects the PPARbeta/delta transactivation of target genes involved in cardiac fatty acid oxidation.	Fatty Acids	275-285	peroxisome proliferator-activated receptor delta	Rattus norvegicus	208-216
15728586-3	2005	Phenylephrine-induced cardiac hypertrophy in neonatal rat cardiomyocytes caused a reduction in the expression of pyruvate dehydrogenase kinase 4 (Pdk4), a target gene of PPARbeta/delta involved in fatty acid utilization, and a fall in palmitate oxidation that was reversed by NF-kappaB inhibitors.	Phenylephrine	0-13	peroxisome proliferator-activated receptor delta	Rattus norvegicus	170-178
15728586-3	2005	Phenylephrine-induced cardiac hypertrophy in neonatal rat cardiomyocytes caused a reduction in the expression of pyruvate dehydrogenase kinase 4 (Pdk4), a target gene of PPARbeta/delta involved in fatty acid utilization, and a fall in palmitate oxidation that was reversed by NF-kappaB inhibitors.	Fatty Acids	197-207	peroxisome proliferator-activated receptor delta	Rattus norvegicus	170-178
15728586-3	2005	Phenylephrine-induced cardiac hypertrophy in neonatal rat cardiomyocytes caused a reduction in the expression of pyruvate dehydrogenase kinase 4 (Pdk4), a target gene of PPARbeta/delta involved in fatty acid utilization, and a fall in palmitate oxidation that was reversed by NF-kappaB inhibitors.	Palmitates	235-244	peroxisome proliferator-activated receptor delta	Rattus norvegicus	170-178
15751073-13	2005	CONCLUSION: Rosiglitazone stimulates IL-1Ra production by a PPARbeta/delta mechanism in activated rat synovial fibroblasts, further contributing to its potential antiarthritic properties and opening new perspectives for the modulation of inflammatory genes by specific PPAR agonists in articular cells.	Rosiglitazone	12-25	peroxisome proliferator-activated receptor delta	Rattus norvegicus	60-68
15721863-3	2005	METHODS AND RESULTS: In cultured neonatal rat cardiomyocytes, the selective PPARbeta/delta activator L-165041 (10 micromol/L) inhibited phenylephrine (PE)-induced protein synthesis ([(3)H]leucine uptake), induction of the fetal-type gene atrial natriuretic factor (ANF) and cardiac myocyte size.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	101-109	peroxisome proliferator-activated receptor delta	Rattus norvegicus	76-84
15721863-3	2005	METHODS AND RESULTS: In cultured neonatal rat cardiomyocytes, the selective PPARbeta/delta activator L-165041 (10 micromol/L) inhibited phenylephrine (PE)-induced protein synthesis ([(3)H]leucine uptake), induction of the fetal-type gene atrial natriuretic factor (ANF) and cardiac myocyte size.	Phenylephrine	136-149	peroxisome proliferator-activated receptor delta	Rattus norvegicus	76-84
15721863-3	2005	METHODS AND RESULTS: In cultured neonatal rat cardiomyocytes, the selective PPARbeta/delta activator L-165041 (10 micromol/L) inhibited phenylephrine (PE)-induced protein synthesis ([(3)H]leucine uptake), induction of the fetal-type gene atrial natriuretic factor (ANF) and cardiac myocyte size.	Phenylephrine	151-153	peroxisome proliferator-activated receptor delta	Rattus norvegicus	76-84
15721863-4	2005	Induction of cardiac hypertrophy by PE stimulation also led to a reduction in the transcript levels of both muscle-type carnitine palmitoyltransferase (50%, P<0.05) and pyruvatedehydrogenase kinase 4 (30%, P<0.05), and these changes were reversed in the presence of the PPARbeta/delta agonist L-165041.	Phenylephrine	36-38	peroxisome proliferator-activated receptor delta	Rattus norvegicus	276-284
15721863-8	2005	Finally, coimmunoprecipitation studies showed that L-165041 strongly enhanced the physical interaction between PPARbeta/delta and the p65 subunit of NF-kappaB, suggesting that increased association between these two proteins is the mechanism responsible for antagonizing NF-kappaB activation by PPARbeta/delta activators.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	51-59	peroxisome proliferator-activated receptor delta	Rattus norvegicus	111-119
15721863-8	2005	Finally, coimmunoprecipitation studies showed that L-165041 strongly enhanced the physical interaction between PPARbeta/delta and the p65 subunit of NF-kappaB, suggesting that increased association between these two proteins is the mechanism responsible for antagonizing NF-kappaB activation by PPARbeta/delta activators.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	51-59	peroxisome proliferator-activated receptor delta	Rattus norvegicus	295-303
15716483-2	2005	In this study, we have evaluated whether PAHs activate the early growth response (EGR-1) gene and bind to peroxisome proliferator-activated receptor alpha (PPAR alpha) and delta (PPAR beta/delta) in cell culture systems.	Polycyclic Aromatic Hydrocarbons	41-45	peroxisome proliferator-activated receptor delta	Rattus norvegicus	179-188
15716483-5	2005	Among them, benz(a)anthracene was found to act as a relatively potent activator of PPAR alpha and PPAR beta/delta, and to significantly enhance EGR-1 transcription.	benz(a)	12-19	peroxisome proliferator-activated receptor delta	Rattus norvegicus	98-107
15716483-5	2005	Among them, benz(a)anthracene was found to act as a relatively potent activator of PPAR alpha and PPAR beta/delta, and to significantly enhance EGR-1 transcription.	anthracene	19-29	peroxisome proliferator-activated receptor delta	Rattus norvegicus	98-107
15728586-8	2005	These results indicate that NF-kappaB activation during cardiac hypertrophy down-regulates PPARbeta/delta activity, leading to a fall in fatty acid oxidation, through a mechanism that involves enhanced protein-protein interaction between the p65 subunit of NF-kappaB and PPARbeta/delta.	Fatty Acids	137-147	peroxisome proliferator-activated receptor delta	Rattus norvegicus	91-99
15728586-8	2005	These results indicate that NF-kappaB activation during cardiac hypertrophy down-regulates PPARbeta/delta activity, leading to a fall in fatty acid oxidation, through a mechanism that involves enhanced protein-protein interaction between the p65 subunit of NF-kappaB and PPARbeta/delta.	Fatty Acids	137-147	peroxisome proliferator-activated receptor delta	Rattus norvegicus	271-279
15211590-6	2004	After 24 hr of exposure, PPARbeta activation by GW0742 was not inherently toxic to cerebellar granule neurons.	GW0742	48-54	peroxisome proliferator-activated receptor delta	Rattus norvegicus	25-33
23056034-1	2012	The aim of this study is to investigate the neuroprotective effects and relevant mechanism of GW0742, an agonist of PPAR-beta, after global cerebral ischemia-reperfusion injury (GCIRI) in rats.	GW0742	94-100	peroxisome proliferator-activated receptor delta	Rattus norvegicus	116-125
11714844-7	2001	Surprisingly, mRNA levels of the fatty acid- activated transcription factors PPARalpha and PPARbeta/delta were reduced in hearts of fasted rats, whereas in livers, fasting led to a marked rise in PPARalpha mRNA.	Fatty Acids	33-43	peroxisome proliferator-activated receptor delta	Rattus norvegicus	91-99
11007938-8	2000	PPAR beta/delta, which is not very well known yet, appears to be more specifically activated by fatty acids.	Fatty Acids	96-107	peroxisome proliferator-activated receptor delta	Rattus norvegicus	0-9
10580838-2	1999	Using ligand-dependent transcription assays, we found that 5-tetradecyloxy-2-furancarboxylic acid (TOFA) transactivates chimeric receptors composed of the glucocorticoid receptor DNA binding domain and the ligand binding regions of PPARalpha, PPARbeta (NUC-1) and LXRbeta (NER) receptors.	5-(tetradecyloxy)-2-furancarboxylic acid	59-97	peroxisome proliferator-activated receptor delta	Rattus norvegicus	243-251
10580838-2	1999	Using ligand-dependent transcription assays, we found that 5-tetradecyloxy-2-furancarboxylic acid (TOFA) transactivates chimeric receptors composed of the glucocorticoid receptor DNA binding domain and the ligand binding regions of PPARalpha, PPARbeta (NUC-1) and LXRbeta (NER) receptors.	5-(tetradecyloxy)-2-furancarboxylic acid	99-103	peroxisome proliferator-activated receptor delta	Rattus norvegicus	243-251
9989800-5	1999	Linoleic acid and carbaprostacyclin, both peroxisome proliferator-activated receptor delta and alpha ligand-activators, were more effective but less specific, stimulating lipid formation in both types of cells.	Linoleic Acid	0-13	peroxisome proliferator-activated receptor delta	Rattus norvegicus	42-90
9989800-5	1999	Linoleic acid and carbaprostacyclin, both peroxisome proliferator-activated receptor delta and alpha ligand-activators, were more effective but less specific, stimulating lipid formation in both types of cells.	carboprostacyclin	18-35	peroxisome proliferator-activated receptor delta	Rattus norvegicus	42-90
12512042-1	2003	BACKGROUND & AIMS: The peroxisome proliferator-activated nuclear receptors (PPAR-alpha, PPAR-beta, and PPAR-gamma), which modulate the expression of genes involved in energy homeostasis, cell cycle, and immune function, may play a role in hepatic stellate cell activation.	Adenosine Monophosphate	12-15	peroxisome proliferator-activated receptor delta	Rattus norvegicus	92-101
12512042-10	2003	Transcriptional activation of PPAR-beta by L165041 enhanced hepatic stellate cell proliferation.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	43-50	peroxisome proliferator-activated receptor delta	Rattus norvegicus	30-39
12086928-7	2002	This response was paralleled by glucose upregulation of the transcription factor sterol regulatory element binding protein 1c (SREBP1c) (ADD1) and downregulation of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-beta (PPARdelta).	Glucose	32-39	peroxisome proliferator-activated receptor delta	Rattus norvegicus	225-234
11304699-11	2001	The striking distal predilection of nabumetone may be, at least partially, explained by distal bowel over-expression of COX-2 and PPAR-delta.	Nabumetone	36-46	peroxisome proliferator-activated receptor delta	Rattus norvegicus	130-140
23056034-8	2012	Our data suggests that the PPAR-beta agonist GW0742 can exert significant neuroprotective effect against GCIRI in rats via PPAR-beta activation and its anti-inflammation effect mediated by the inhibition of expression and activation of NF-kappaB in the hippocampus.	GW0742	45-51	peroxisome proliferator-activated receptor delta	Rattus norvegicus	27-36
23056034-8	2012	Our data suggests that the PPAR-beta agonist GW0742 can exert significant neuroprotective effect against GCIRI in rats via PPAR-beta activation and its anti-inflammation effect mediated by the inhibition of expression and activation of NF-kappaB in the hippocampus.	GW0742	45-51	peroxisome proliferator-activated receptor delta	Rattus norvegicus	123-132
34736532-2	2021	Peroxisome proliferators-activated receptor (PPAR) beta/delta has a positive regulatory effect on bone turnover under physiologic glucose concentration; however, the regulatory effect in diabetes mellitus has not been investigated yet.	Glucose	130-137	peroxisome proliferator-activated receptor delta	Rattus norvegicus	0-61
34947939-7	2021	Intracellular adenosine monophosphate-activated protein kinase, peroxisome proliferator-activated receptor delta (PPARdelta), and perilipin levels were increased by adenine after HR stimulation.	Adenine	165-172	peroxisome proliferator-activated receptor delta	Rattus norvegicus	64-112
34947939-7	2021	Intracellular adenosine monophosphate-activated protein kinase, peroxisome proliferator-activated receptor delta (PPARdelta), and perilipin levels were increased by adenine after HR stimulation.	Adenine	165-172	peroxisome proliferator-activated receptor delta	Rattus norvegicus	114-123
31364177-1	2019	GW501516-activated peroxisome proliferator-activated receptor (PPAR) beta/delta and G-protein-coupled receptor (GPR) 40 were shown to protect pancreatic beta cells against lipoapoptosis.	GW 501516	0-8	peroxisome proliferator-activated receptor delta	Rattus norvegicus	19-79
32612543-4	2020	We sought to determine whether reduced PPARdelta content in insulin-resistant rat skeletal muscle of a non-obese rat model of T2DM (Goto-Kakizaki, GK) ameliorate the inhibitory effect of fatty acid (i.e., palmitoylcarnitine) on mitochondrial carbohydrate oxidization (i.e., pyruvate) in muscle fibers.	Fatty Acids	187-197	peroxisome proliferator-activated receptor delta	Rattus norvegicus	39-48
32612543-4	2020	We sought to determine whether reduced PPARdelta content in insulin-resistant rat skeletal muscle of a non-obese rat model of T2DM (Goto-Kakizaki, GK) ameliorate the inhibitory effect of fatty acid (i.e., palmitoylcarnitine) on mitochondrial carbohydrate oxidization (i.e., pyruvate) in muscle fibers.	Palmitoylcarnitine	205-223	peroxisome proliferator-activated receptor delta	Rattus norvegicus	39-48
32612543-4	2020	We sought to determine whether reduced PPARdelta content in insulin-resistant rat skeletal muscle of a non-obese rat model of T2DM (Goto-Kakizaki, GK) ameliorate the inhibitory effect of fatty acid (i.e., palmitoylcarnitine) on mitochondrial carbohydrate oxidization (i.e., pyruvate) in muscle fibers.	Carbohydrates	242-254	peroxisome proliferator-activated receptor delta	Rattus norvegicus	39-48
32612543-4	2020	We sought to determine whether reduced PPARdelta content in insulin-resistant rat skeletal muscle of a non-obese rat model of T2DM (Goto-Kakizaki, GK) ameliorate the inhibitory effect of fatty acid (i.e., palmitoylcarnitine) on mitochondrial carbohydrate oxidization (i.e., pyruvate) in muscle fibers.	Pyruvic Acid	274-282	peroxisome proliferator-activated receptor delta	Rattus norvegicus	39-48
32612543-14	2020	Conclusion: With competing fuels, the presence of fatty acids diminishes mitochondria ability to utilize carbohydrate derived substrates in insulin-resistant muscle despite reduced PPARdelta content.	Fatty Acids	50-61	peroxisome proliferator-activated receptor delta	Rattus norvegicus	181-190
30129179-0	2018	GW0742 activates peroxisome proliferator-activated receptor delta to reduce free radicals and alleviate cardiac hypertrophy induced by hyperglycemia in cultured H9c2 cells.	GW0742	0-6	peroxisome proliferator-activated receptor delta	Rattus norvegicus	17-65
31384284-5	2019	Results: Our data showed that palmitate and PPAR agonists including WY14643 (PPARalpha), GW501516 (PPARbeta/delta), rosiglitazone (PPARgamma) in vitro all induced PLIN5 expression in INS-1 cells.	Palmitates	30-39	peroxisome proliferator-activated receptor delta	Rattus norvegicus	99-107
31384284-5	2019	Results: Our data showed that palmitate and PPAR agonists including WY14643 (PPARalpha), GW501516 (PPARbeta/delta), rosiglitazone (PPARgamma) in vitro all induced PLIN5 expression in INS-1 cells.	GW 501516	89-97	peroxisome proliferator-activated receptor delta	Rattus norvegicus	99-107
30551401-7	2019	RESULTS: Naringenin (0.1, 1, 10 mumol/L) inhibited cardiomyocyte hypertrophy in a concentration-dependent manner (P < 0.05), up-regulated the expressions of PPARalpha, PPARbeta, PPARgamma and CYP2J3 (P < 0.05), and increased the level of 14,15-EET (P < 0.05).	naringenin	9-19	peroxisome proliferator-activated receptor delta	Rattus norvegicus	171-179
30551401-9	2019	Meanwhile, MK886, a PPARalpha antagonist, GSK0660, a PPARbeta antagonist, and GW9662, a PPARgamma antagonist, reversed the protection of naringenin on cardiomyocytes (P < 0.05), and abrogated the up-regulation of CYP2J3-EET produced by naringenin (P < 0.05).	naringenin	137-147	peroxisome proliferator-activated receptor delta	Rattus norvegicus	53-61
30129179-3	2018	Then, H9c2 cells incubated with high glucose to induce hypertrophy were used to investigate using GW0742 to activate PPARdelta.	GW0742	98-104	peroxisome proliferator-activated receptor delta	Rattus norvegicus	117-126
30129179-9	2018	These effects of GW0742 were dose-dependently inhibited by GSK0660 indicating an activation of PPARdelta by GW0742 to alleviate cardiac hypertrophy.	GW0742	17-23	peroxisome proliferator-activated receptor delta	Rattus norvegicus	95-104
30129179-9	2018	These effects of GW0742 were dose-dependently inhibited by GSK0660 indicating an activation of PPARdelta by GW0742 to alleviate cardiac hypertrophy.	GSK0660	59-66	peroxisome proliferator-activated receptor delta	Rattus norvegicus	95-104
30129179-9	2018	These effects of GW0742 were dose-dependently inhibited by GSK0660 indicating an activation of PPARdelta by GW0742 to alleviate cardiac hypertrophy.	GW0742	108-114	peroxisome proliferator-activated receptor delta	Rattus norvegicus	95-104
30129179-13	2018	Taken together, these findings suggest that PPARdelta agonists can inhibit free radicals, resulting in lower cellular calcium for reduction of hypertrophic signaling to alleviate cardiac hypertrophy in H9c2 cells.	Calcium	118-125	peroxisome proliferator-activated receptor delta	Rattus norvegicus	44-53
29778745-14	2018	The results indicated that the central injection of abscisic acid has potent pain-relieving property which is mediated partly via the PPAR beta/delta and opioid signaling.	Abscisic Acid	52-65	peroxisome proliferator-activated receptor delta	Rattus norvegicus	134-143
30086290-3	2018	In the present study, we hypothesized that PPAR-beta/delta agonist GW0742 can activate miR-17-5p, consequently inhibiting TXNIP and ASK1/p38 pathway leading to attenuation of apoptosis.	GW0742	67-73	peroxisome proliferator-activated receptor delta	Rattus norvegicus	43-52
30086290-9	2018	Furthermore, GW0742 treatment increased PPAR-beta/delta nuclear expression and miR-17-5p level and reduced TXNIP in ipsilateral hemisphere after HI, resulting in inhibition of ASK1/p38 pathway and attenuation of apoptosis.	GW0742	13-19	peroxisome proliferator-activated receptor delta	Rattus norvegicus	40-49
30086290-11	2018	For the first time, we provide evidence that intranasal administration of PPAR-beta/delta agonist GW0742 attenuated neuronal apoptosis at least in part via PPAR-beta/delta/miR-17/TXNIP pathway.	GW0742	98-104	peroxisome proliferator-activated receptor delta	Rattus norvegicus	74-83
30086290-11	2018	For the first time, we provide evidence that intranasal administration of PPAR-beta/delta agonist GW0742 attenuated neuronal apoptosis at least in part via PPAR-beta/delta/miR-17/TXNIP pathway.	GW0742	98-104	peroxisome proliferator-activated receptor delta	Rattus norvegicus	156-165
29636848-7	2018	The beneficial effects of DMF treatment include an increase in renal Nrf2 gene expression, reduction of oxidative stress, decrease in plasma asymmetric dimethylarginine (ADMA) and renal soluble epoxide hydrolase protein levels, increase in the l-arginine-to-ADMA ratio, and activation of genes related to nutrient sensing and autophagy (e.g., Pparb, Pparg, Ppargc1a, Ulk1, and Atg5).	Dimethyl Fumarate	26-29	peroxisome proliferator-activated receptor delta	Rattus norvegicus	343-348
30046379-2	2018	Here, we demonstrated the potentiality of peroxisome proliferator-activated receptor (PPAR)beta/delta activation in attenuating high glucose-induced oxidative stress in endothelial cells and diabetic rats, pointing to the involvement of nuclear factor erythroid 2-related factor 2 (Nrf2).	Glucose	133-140	peroxisome proliferator-activated receptor delta	Rattus norvegicus	86-95
30046379-3	2018	HUVECs exposed to high glucose showed increased levels of reactive oxygen species (ROS) and upregulated NOX-2, NOX-4, Nrf2, and NQO-1 effects that were significantly reversed by the PPARbeta/delta agonists GW0742 and L165041.	Glucose	23-30	peroxisome proliferator-activated receptor delta	Rattus norvegicus	182-190
30046379-3	2018	HUVECs exposed to high glucose showed increased levels of reactive oxygen species (ROS) and upregulated NOX-2, NOX-4, Nrf2, and NQO-1 effects that were significantly reversed by the PPARbeta/delta agonists GW0742 and L165041.	Reactive Oxygen Species	58-81	peroxisome proliferator-activated receptor delta	Rattus norvegicus	182-190
30046379-3	2018	HUVECs exposed to high glucose showed increased levels of reactive oxygen species (ROS) and upregulated NOX-2, NOX-4, Nrf2, and NQO-1 effects that were significantly reversed by the PPARbeta/delta agonists GW0742 and L165041.	Reactive Oxygen Species	83-86	peroxisome proliferator-activated receptor delta	Rattus norvegicus	182-190
30046379-3	2018	HUVECs exposed to high glucose showed increased levels of reactive oxygen species (ROS) and upregulated NOX-2, NOX-4, Nrf2, and NQO-1 effects that were significantly reversed by the PPARbeta/delta agonists GW0742 and L165041.	GW0742	206-212	peroxisome proliferator-activated receptor delta	Rattus norvegicus	182-190
30046379-3	2018	HUVECs exposed to high glucose showed increased levels of reactive oxygen species (ROS) and upregulated NOX-2, NOX-4, Nrf2, and NQO-1 effects that were significantly reversed by the PPARbeta/delta agonists GW0742 and L165041.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	217-224	peroxisome proliferator-activated receptor delta	Rattus norvegicus	182-190
30046379-4	2018	Both PPARbeta/delta agonists, in a concentration-dependent manner, induced transcriptional and protein upregulation of heme oxygenase-1 (HO-1) under low- and high-glucose conditions.	Glucose	163-170	peroxisome proliferator-activated receptor delta	Rattus norvegicus	5-13